DesignationRef.Download
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERSJ Prev Alz Dis 2015;2(4):269-39638208
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERSJ Prev Alz Dis 2016;4:262-37918254
THE ALZHEIMER’S PREVENTION CLINIC AT WEILL CORNELL MEDICAL COLLEGE / NEW YORK - PRESBYTERIAN HOSPITAL: RISK STRATIFICATION AND PERSONALIZED EARLY INTERVENTION J Prev Alz Dis 2015;2(4):254-2667175
ENDPOINTS FOR PRE-DEMENTIA AD TRIALS: A REPORT FROM THE EU/US/CTAD TASK FORCEJ Prev Alz Dis 2015;2(2):128-1357150
RE-ENGINEERING ALZHEIMER CLINICAL TRIALS: GLOBAL ALZHEIMER’S PLATFORM NETWORKJ Prev Alz Dis 2016;3(2):114-1205888
Clinical Trials and Aging: 13th Conference Clinical Trials Alzheimer’s Disease, November 4-7, 2020J Prev Alz Dis 2020;7(S1):S55-S1195137
VITAMIN D AND DEMENTIAJ Prev Alz Dis 2016;3(1):43-524789
CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION POTENTIALJ Prev Alz Dis 2017;4(3):149-1564614
A COMBINED MEASURE OF COGNITION AND FUNCTION FOR CLINICAL TRIALS: THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS) J Prev Alz Dis 2015;2(4):227-2414230
CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT” J Prev Alz Dis 2016;3(4):219-2283866
A PERSONALIZED 12-WEEK “BRAIN FITNESS PROGRAM” FOR IMPROVING COGNITIVE FUNCTION AND INCREASING THE VOLUME OF HIPPOCAMPUS IN ELDERLY WITH MILD COGNITIVE IMPAIRMENTJ Prev Alz Dis 2016;3(3):133-1373580
PRECLINICAL AND CLINICAL DEVELOPMENT OF ABBV-8E12, A HUMANIZED ANTI-TAU ANTIBODY, FOR TREATMENT OF ALZHEIMER’S DISEASE AND OTHER TAUOPATHIESJ Prev Alz Dis 2017;4(4):236-2413182
REVERSIBLE AND SPECIES-SPECIFIC DEPIGMENTATION EFFECTS OF AZD3293, A BACE INHIBITOR FOR THE TREATMENT OF ALZHEIMER’S DISEASE, ARE RELATED TO BACE2 INHIBITION AND CONFINED TO EPIDERMIS AND HAIR J Prev Alz Dis 2016;3(4):202-2182969
BRIDGING THE GAP BETWEEN RESEARCH AND CLINICAL PRACTICE IN ASYMPTOMATIC ALZHEIMER’S DISEASEJ Prev Alz Dis 2016;3(1):30-422760
DEFINING DISEASE MODIFYING THERAPY FOR ALZHEIMER’S DISEASEJ Prev Alz Dis 2017;4(2):109-1152758
COMBINATION THERAPY OF ANTI-TAU AND ANTI-AMYLOID DRUGS FOR DISEASE MODIFICATION IN EARLY-STAGE ALZHEIMER’S DISEASE: SOCIO-ECONOMIC CONSIDERATIONS MODELED ON TREATMENTS FOR TUBERCULOSIS, HIV/AIDS AND BREAST CANCER J Prev Alz Dis 2016;3(3):164-1722682
ETHICAL ISSUES IN THE DEVELOPMENT OF READINESS COHORTS IN ALZHEIMER’S DISEASE RESEARCHJ Prev Alz Dis 2017;4(2):125-1312456
CLINICAL AND ECONOMIC CHARACTERISTICS OF MILESTONES ALONG THE CONTINUUM OF ALZHEIMER’S DISEASE: TRANSFORMING FUNCTIONAL SCORES INTO LEVELS OF DEPENDENCEJ Prev Alz Dis 2015;2(2):115-1202442
NEFLAMAPIMOD: CLINICAL PHASE 2B-READY ORAL SMALL MOLECULE INHIBITOR OF P38? TO REVERSE SYNAPTIC DYSFUNCTION IN EARLY ALZHEIMER’S DISEASEJ Prev Alz Dis 2017;4(4):273-2782387
BRIDGING THE TRANSLATION GAP: FROM DEMENTIA RISK ASSESSMENT TO ADVICE ON RISK REDUCTIONJ Prev Alz Dis 2015;2(3):189-1982272
THE RELATIONSHIP OF OMEGA 3 POLYUNSATURATED FATTY ACIDS IN RED BLOOD CELL MEMBRANES WITH COGNITIVE FUNCTION AND BRAIN STRUCTURE: A REVIEW FOCUSSED ON ALZHEIMER’S DISEASEJ Prev Alz Dis 2018;5(1):78-842262
THE ALZHEIMER’S PREVENTION INITIATIVE GENERATION PROGRAM: EVALUATING CNP520 EFFICACY IN THE PREVENTION OF ALZHEIMER’S DISEASEJ Prev Alz Dis 2017;4(4):242-2462179
EVALUATION OF THE NEUROPROTECTIVE POTENTIAL OF N-ACETYLCYSTEINE FOR PREVENTION AND TREATMENT OF COGNITIVE AGING AND DEMENTIAJ Prev Alz Dis 2017;4(3):201-2062152
POST HOC EVIDENCE FOR AN ADDITIVE EFFECT OF MEMANTINE AND DONEPEZIL: CONSISTENT FINDINGS FROM DOMINO-AD STUDY AND MEMANTINE CLINICAL TRIAL PROGRAMJ Prev Alz Dis 2015;2(3):165-1712119
CORRELATION BETWEEN COGNITION AND FUNCTION ACROSS THE SPECTRUM OF ALZHEIMER’S DISEASEJ Prev Alz Dis 2016;3(3):138-1442067
FROM BRAIN DISEASE TO BRAIN HEALTH: PRIMARY PREVENTION OF ALZHEIMER’S DISEASE AND RELATED DISORDERS IN A HEALTH SYSTEM USING AN ELECTRONIC MEDICAL RECORD-BASED APPROACHJ Prev Alz Dis 2017;4(3):157-1642023
SHORT-TERM IMPACT OF A COMBINED NUTRACEUTICAL ON COGNITIVE FUNCTION, PERCEIVED STRESS AND DEPRESSION IN YOUNG ELDERLY WITH COGNITIVE IMPAIRMENT: A PILOT, DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL J Prev Alz Dis 2017;4(1):12-152020
MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER’S DISEASE: DESIGN AND BASELINE DATAJ Prev Alz Dis 2014;1(1):13-221914
SAFETY AND EFFICACY OF LEMBOREXANT IN PATIENTS WITH IRREGULAR SLEEP-WAKE RHYTHM DISORDER AND ALZHEIMER’S DISEASE DEMENTIA: RESULTS FROM A PHASE 2 RANDOMIZED CLINICAL TRIALJ Prev Alz Dis 2021;1(8):7-181818
B-VITAMIN THERAPY FOR KIDNEY TRANSPLANT RECIPIENTS LOWERS HOMOCYSTEINE AND IMPROVES SELECTIVE COGNITIVE OUTCOMES IN THE RANDOMIZED FAVORIT ANCILLARY COGNITIVE TRIALJ Prev Alz Dis 2017;4(3):174-1821757
ANTI-TAU TRIALS FOR ALZHEIMER’S DISEASE: A REPORT FROM THE EU/US/CTAD TASK FORCEJ Prev Alz Dis 2019;6(3):157-1631600
ALZHEIMER’S DISEASE DRUG DEVELOPMENT PIPELINE 2020J Prev Alz Dis 2020;7(2):66-671578
‘ALZHEIMER’S PROGRESSION SCORE’: DEVELOPMENT OF A BIOMARKER SUMMARY OUTCOME FOR AD PREVENTION TRIALSJ Prev Alz Dis 2016;3(4):229-2351557
DEPENDENCE LEVELS AS INTERIM CLINICAL MILESTONES ALONG THE CONTINUUM OF ALZHEIMER’S DISEASE: 18-MONTH RESULTS FROM THE GERAS OBSERVATIONAL STUDYJ Prev Alz Dis 2017;4(2):72-801552
THE ROSAS COHORT: A PROSPECTIVE, LONGITUDINAL STUDY OF BIOMARKERS FOR ALZHEIMER’S DISEASE. STRATEGY, METHODS AND INITIAL RESULTSJ Prev Alz Dis 2017;4(3):183-1931547
THE CASE FOR USING ACTIGRAPHY GENERATED SLEEP AND ACTIVITY ENDPOINTS IN ALZHEIMER’S DISEASE CLINICAL TRIALSJ Prev Alz Dis 2016;3(3):173-1761538
INTEGRATED CARE FOR OLDER PEOPLE AND THE IMPLEMENTATION IN THE INSPIRE CARE COHORTJ Prev Alz Dis 2020;7(2):70-741533
RATIONALE AND STRUCTURE FOR A NEW CENTER FOR STUDIES ON PREVENTION OF ALZHEIMER’S DISEASE (STOP-AD)J Prev Alz Dis 2016;3(4):236-2421508
PIMAVANSERIN IN ALZHEIMER’S DISEASE PSYCHOSIS: EFFICACY IN PATIENTS WITH MORE PRONOUNCED PSYCHOTIC SYMPTOMSJ Prev Alz Dis 2019;6(1):27-331447
HEALTH LITERACY IN INDIVIDUALS AT RISK FOR ALZHEIMER’S DEMENTIA: A SYSTEMATIC REVIEWJ Prev Alz Dis 2020;7(1):47-551429
FATTY ACIDS AND ALZHEIMER’S DISEASE: EVIDENCE ON COGNITION AND CORTICAL ?-AMYLOID FROM SECONDARY ANALYSES OF THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIALJ Prev Alz Dis 2018;5(3):168-1701344
VITAMIN E SUPPLEMENTATION REDUCES CELLULAR LOSS IN THE BRAIN OF A PREMATURE AGING MOUSE MODELJ Prev Alz Dis 2017;4(4):226-2351318
PSYCHOMETRIC PROPERTIES OF THE CLINICAL DEMENTIA RATING – SUM OF BOXES AND OTHER COGNITIVE AND FUNCTIONAL OUTCOMES IN A PRODROMAL ALZHEIMER’S DISEASE POPULATIONJ Prev Alz Dis 2021;2(8):151-1601302
NANOROBOTS THE FUTURE OF NEUROLOGY: A PERSPECTIVE ON ALZHEIMER’S DISEASEJ Prev Alz Dis 2018;5(2):155-1561289
WHAT HAVE WE LEARNED FROM EXPEDITION III AND EPOCH TRIALS? PERSPECTIVE OF THE CTAD TASK FORCEJ Prev Alz Dis 2018;5(3):171-1701286
NUTRITION-BASED APPROACHES IN CLINICAL TRIALS TARGETING COGNITIVE FUNCTION: HIGHLIGHTS OF THE CTAD 2020J Prev Alz Dis 2021;2(8):118-1221286
IDENTIFYING BETTER OUTCOME MEASURES TO IMPROVE TREATMENT OF AGITATION IN DEMENTIA: A REPORT FROM THE EU/US/CTAD TASK FORCEJ Prev Alz Dis 2018;5(2):98-1021285
AN ACTION PLAN TO FACE THE CHALLENGE OF DEMENTIA: INTERNATIONAL STATEMENT ON DEMENTIA FROM IAP FOR HEALTHJ Prev Alz Dis 2018;5(3):207-2121177
REGISTRIES AND COHORTS TO ACCELERATE EARLY PHASE ALZHEIMER’S TRIALS. A REPORT FROM THE E.U./U.S. CLINICAL TRIALS IN ALZHEIMER’S DISEASE TASK FORCEJ Prev Alz Dis 2016;3(2):68-741175
THE FUTURE OF ANTI-AMYLOID TRIALSJ Prev Alz Dis 2020;3(7):146-1511169
PLASMA BIOMARKERS OF AD EMERGING AS ESSENTIAL TOOLS FOR DRUG DEVELOPMENT: AN EU/US CTAD TASK FORCE REPORTJ Prev Alz Dis 2019;6(3):169-1731157
PIMAVANSERIN: POTENTIAL TREATMENT FOR DEMENTIA-RELATED PSYCHOSISJ Prev Alz Dis 2018;5(4):253-2581107
EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN PRIMARY CAREJ Prev Alz Dis 2020;3(7):165-1701085
NON-AMYLOID APPROACHES TO DISEASE MODIFICATION FOR ALZHEIMER’S DISEASE: AN EU/US CTAD TASK FORCE REPORTJ Prev Alz Dis 2020;3(7):152-1571076
MULTIDOMAIN INTERVENTIONS TO PREVENT COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, AND DEMENTIA: FROM FINGER TO WORLD-WIDE FINGERSJ Prev Alz Dis 2020;7(1):29-361070
Clinical Trials and Aging: 13th Conference Clinical Trials Alzheimer’s Disease, November 4-7, 2020J Prev Alz Dis 2020;7(S1):S2-S541068
IMPLICATIONS FOR BACE1 INHIBITOR CLINICAL TRIALS: ADULT CONDITIONAL BACE1 KNOCKOUT MICE EXHIBIT AXONAL ORGANIZATION DEFECTS IN THE HIPPOCAMPUSJ Prev Alz Dis 2019;6(2):78-841036
APPLICATION OF THE NIA-AA RESEARCH FRAMEWORK: TOWARDS A BIOLOGICAL DEFINITION OF ALZHEIMER’S DISEASE USING CEREBROSPINAL FLUID BIOMARKERS IN THE AIBL STUDYJ Prev Alz Dis 2019;6(4):248-2551020
CAN DIGITAL TECHNOLOGY ADVANCE THE DEVELOPMENT OF TREATMENTS FOR ALZHEIMER’S DISEASE?J Prev Alz Dis 2019;6(4):217-2201011
THE EUROPEAN PREVENTION OF ALZHEIMER’S DEMENTIA (EPAD) LONGITUDINAL COHORT STUDY: BASELINE DATA RELEASE V500.0J Prev Alz Dis 2020;7(1):8-131009
RATIONALE FOR EARLY DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT (MCI) SUPPORTED BY EMERGING DIGITAL TECHNOLOGIESJ Prev Alz Dis 2020;3(7):158-164966
REVISITING THE HALLMARKS OF AGING TO IDENTIFY MARKERS OF BIOLOGICAL AGEJ Prev Alz Dis 2020;7(1):56-64951
UTILIZATION OF OBSERVATIONAL DATA AS A PROXY COHORT FOR COMPARISON PURPOSES WITH OPEN-LABEL STUDY RESULTS: AN EXAMPLE FROM ALZHEIMER’S DISEASEJ Prev Alz Dis 2019;6(2):90-99941
THE INTERRELATIONSHIP BETWEEN INSULIN-LIKE GROWTH FACTOR 1, APOLIPOPROTEIN E Ε4, LIFESTYLE FACTORS, AND THE AGING BODY AND BRAINJ Prev Alz Dis 2020;4(7):265-273933
A MISSED OPPORTUNITY FOR DEMENTIA PREVENTION? CURRENT CHALLENGES FOR EARLY DETECTION AND MODERN-DAY SOLUTIONSJ Prev Alz Dis 2020;4(7):291-293923
A TURNING POINT IN ALZHEIMER’S RESEARCH: HARMONIZED RESEARCH STRATEGIES AND NOVEL INVESTMENTS IN PUBLIC HEALTH INFRASTRUCTURE ARE REENERGIZING THE FIELD, AND REKINDLING HOPE FOR THOSE AFFECTED BY ALZHEIMER’S AND RELATED DEMENTIASJ Prev Alz Dis 2019;6(4):214-216922
CORTICAL Β-AMYLOID IN OLDER ADULTS IS ASSOCIATED WITH MULTIDOMAIN INTERVENTIONS WITH AND WITHOUT OMEGA 3 POLYUNSATURATED FATTY ACID SUPPLEMENTATIONJ Prev Alz Dis 2020;7(2):128-134896
EU/US/CTAD TASK FORCE: LESSONS LEARNED FROM RECENT AND CURRENT ALZHEIMER’S PREVENTION TRIALSJ Prev Alz Dis 2017;4(2):116-124887
TARGETING LIFESTYLE BEHAVIOR TO IMPROVE BRAIN HEALTH: USER-EXPERIENCES OF AN ONLINE PROGRAM FOR INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINEJ Prev Alz Dis 2020;3(7):184-194867
DIET AS A RISK FACTOR FOR COGNITIVE DECLINE IN AFRICAN AMERICANS AND CAUCASIANS WITH A PARENTAL HISTORY OF ALZHEIMER’S DISEASE: A CROSS- SECTIONAL PILOT STUDY DIETARY PATTERNSJ Prev Alz Dis 2019;6(1):50-55850
CORRELATION OF CSF- AND MRI-BIOMARKERS AND PROGRESSION OF COGNITIVE DECLINE IN AN OPEN LABEL MCI TRIALJ Prev Alz Dis 2018;5(3):202-206836
EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN AN AT-HOME SETTINGJ Prev Alz Dis 2020;3(7):171-178829
ALZHEIMER’S DISEASE COMPOSITE SCORE: A POST-HOC ANALYSIS USING DATA FROM THE LIPIDIDIET TRIAL IN PRODROMAL ALZHEIMER’S DISEASEJ Prev Alz Dis 2019;6(4):232-236818
IMPACT OF THE COVID-19 OUTBREAK ON THE CLINICAL AND RESEARCH ACTIVITIES OF MEMORY CLINICS: AN ALZHEIMER’S DISEASE CENTER FACING THE COVID-19 CRISISJ Prev Alz Dis 2020;3(7):197-198811
ESTABLISHING CLINICAL RELEVANCE IN PRECLINICAL ALZHEIMER’S DISEASEJ Prev Alz Dis 2015;2(2):85-87779
DIGITAL SCREENING FOR COGNITIVE IMPAIRMENT – A PROOF OF CONCEPT STUDYJ Prev Alz Dis 2021;2(8):127-134773
SCREENING FOR MILD COGNITIVE IMPAIRMENT: THERE IS THE WILL BUT IS THERE A WAY?J Prev Alz Dis 2020;3(7):144-145768
COGNITIVE/CLINICAL ENDPOINTS FOR PRE-DEMENTIA AD TRIALSJ Prev Alz Dis 2015;2(2):82-84762
TREATABLE VASCULAR RISK AND COGNITIVE PERFORMANCE IN PERSONS AGED 35 YEARS OR OLDER: LONGITUDINAL STUDY OF SIX YEARSJ Prev Alz Dis 2019;6(1):42-49749
PREDICTING AMYLOID BURDEN TO ACCELERATE RECRUITMENT OF SECONDARY PREVENTION CLINICAL TRIALSJ Prev Alz Dis 2020;4(7):213-218741
THE ROLE OF CLINICAL TRIALS IN PRECLINICAL ALZHEIMER’S DISEASE DRUG DEVELOPMENT PROGRAMSJ Prev Alz Dis 2020;4(7):288-290735
POLYGENIC RISK SCORE ANALYSIS OF ALZHEIMER’S DISEASE IN CASES WITHOUT APOE4 OR APOE2 ALLELESJ Prev Alz Dis 2019;6(1):16-19734
HOW WILL ADUCANUMAB APPROVAL IMPACT AD RESEARCH?J Prev Alz Dis 2021;4(8):391-392732
ADUCANUMAB: APPROPRIATE USE RECOMMENDATIONSJ Prev Alz Dis 2021;4(8):398-410728
POSSIBLE ENDPOINTS IN A PRODROMAL ALZHEIMER’S DISEASE TRIALJ Prev Alz Dis 2015;2(2):88-90716
TWO RANDOMIZED PHASE 3 STUDIES OF ADUCANUMAB IN EARLY ALZHEIMER’S DISEASEJ Prev Alz Dis 2022;2(9):197-210716
IMPACT OF ADUHELM APPROVAL ON CARE AND POLICYJ Prev Alz Dis 2021;4(8):396-397713
THE COMPUTERIZED COGNITIVE COMPOSITE (C3) IN A4, AN ALZHEIMER’S DISEASE SECONDARY PREVENTION TRIALJ Prev Alz Dis 2021;1(8):59-67711
THE EPIDEMIOLOGY OF ALZHEIMER’S DISEASE MODIFIABLE RISK FACTORS AND PREVENTIONJ Prev Alz Dis 2021;3(8):313-321710
THE ALZHEIMER’S PREVENTION REGISTRY: A LARGE INTERNET-BASED PARTICIPANT RECRUITMENT REGISTRY TO ACCELERATE REFERRALS TO ALZHEIMER’S-FOCUSED STUDIESJ Prev Alz Dis 2020;4(7):242-250695
A FRAMEWORK FOR DEVELOPING PHARMACOTHERAPY FOR AGITATION IN ALZHEIMER’S DISEASE: RECOMMENDATIONS OF THE ISCTM* WORKING GROUPJ Prev Alz Dis 2020;4(7):274-282685
APPLICATION OF DIGITAL COGNITIVE BIOMARKERS FOR ALZHEIMER’S DISEASE: IDENTIFYING COGNITIVE PROCESS CHANGES AND IMPENDING COGNITIVE DECLINEJ Prev Alz Dis 2021;2(8):123-126685
EVALUATION OF THE FISCAL COSTS AND CONSEQUENCES OF ALZHEIMER’S DISEASE IN GERMANY: MICROSIMULATION OF PATIENTS’ AND CAREGIVERS’ PATHWAYSJ Prev Alz Dis 2022;4(9):758-768681
THIRTY-SIX-MONTH AMYLOID POSITRON EMISSION TOMOGRAPHY RESULTS SHOW CONTINUED REDUCTION IN AMYLOID BURDEN WITH SUBCUTANEOUS GANTENERUMABJ Prev Alz Dis 2021;1(8):3-6645
TOULOUSE ALZHEIMER’S CLINICAL RESEARCH CENTER RECOVERY AFTER THE COVID-19 CRISIS: TELEMEDICINE AN INNOVATIVE SOLUTION FOR CLINICAL RESEARCH DURING THE CORONAVIRUS PANDEMICJ Prev Alz Dis 2020;4(7):301-304644
DIAGNOSIS OF EARLY ALZHEIMER’S DISEASE: CLINICAL PRACTICE IN 2021J Prev Alz Dis 2021;3(8):371-386638
NEXT-GENERATION ALZHEIMER’S THERAPEUTICS: LEVERAGING DEEP BIOLOGYJ Prev Alz Dis 2020;3(7):138-139630
THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD) PROJECT: AN OVERVIEWJ Prev Alz Dis 2020;4(7):208-212614
AMYLOID AND APOE STATUS OF SCREENED SUBJECTS IN THE ELENBECESTAT MISSIONAD PHASE 3 PROGRAMJ Prev Alz Dis 2021;2(8):218-223605
THE US EXPERT PANEL ON THE APPROPRIATE USE RECOMMENDATIONS OF ADUCANUMAB IN CLINICAL PRACTICEJ Prev Alz Dis 2021;4(8):411605
THE ROLE OF FUTILITY ANALYSES IN AD CLINICAL TRIALSJ Prev Alz Dis 2020;7(1):7599
PUBLIC POLICY SHOULD FOSTER ALZHEIMER’S TREATMENT AVAILABILITY: COMMENT ON THE DRAFT US MEDICARE DECISION TO LIMIT PAYMENT FOR ADUCANUMAB (ADUHELMTM) TO PATIENTS PARTICIPATING IN CLINICAL TRIALSJ Prev Alz Dis 2022;2(9):241-246596
CONSEQUENCES OF THE FDA DECISION ON ADUCANUMAB FOR PATIENT CARE AND RESEARCHJ Prev Alz Dis 2021;4(8):393-395586
NEW HOPE FOR ALZHEIMER’S DISEASEJ Prev Alz Dis 2021;3(8):238-239583
THE TRIAL-READY COHORT FOR PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD): EXPERIENCE FROM THE FIRST 3 YEARSJ Prev Alz Dis 2020;4(7):234-241576
POLYGENIC RISK SCORING IS AN EFFECTIVE APPROACH TO PREDICT THOSE INDIVIDUALS MOST LIKELY TO DECLINE COGNITIVELY DUE TO ALZHEIMER’S DISEASEJ Prev Alz Dis 2021;1(8):78-83575
VIEWPOINT: WHEN IT COMES TO LECANEMAB (AND DONANEMAB), HOW MIGHT WE THINK ABOUT ‘REASONABLE AND NECESSARY’?J Prev Alz Dis 2023;3(10):342-343572
Clinical Trials and Aging: 14th Conference Clinical Trials Alzheimer’s Disease, November 9-12, 2021J Prev Alz Dis 2021;8(S1):S73-S170562
LETTER TO THE EDITOR REFERRING TO AISEN, P.S. AND R. RAMAN, FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS. THE JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE, 2020J Prev Alz Dis 2020;4(7):299-300561
INTRANASAL INSULIN REDUCES WHITE MATTER HYPERINTENSITY PROGRESSION IN ASSOCIATION WITH IMPROVEMENTS IN COGNITION AND CSF BIOMARKER PROFILES IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASEJ Prev Alz Dis 2021;3(8):240-248544
ADUCANUMAB: APPROPRIATE USE RECOMMENDATIONSJ Prev Alz Dis 2021;4(8):412-413542
RECRUITMENT INTO THE ALZHEIMER PREVENTION TRIALS (APT) WEBSTUDY FOR A TRIAL-READY COHORT FOR PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE (TRCPAD)J Prev Alz Dis 2020;4(7):219-225523
Clinical Trials and Aging: 14th Conference Clinical Trials Alzheimer’s Disease, November 9-12, 2021J Prev Alz Dis 2021;8(S1):S1-S72523
ACCELERATING PRECLINICAL ALZHEIMER’S CLINICAL TRIALS THROUGH A TRIAL-READY COHORT WITH DIVERSE REPRESENTATIONJ Prev Alz Dis 2020;4(7):204-205517
THE SARS-COV-2 PANDEMIC AND THE BRAVE NEW DIGITAL WORLD OF ENVIRONMENTAL ENRICHMENT TO PREVENT BRAIN AGING AND COGNITIVE DECLINEJ Prev Alz Dis 2020;4(7):294-298502
AUTHORS RESPONSE TO UMBRICHT D, LETTER TO THE EDITOR REFERRING FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS. THE JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE, 2020J Prev Alz Dis 2020;4(7):300497
ITEM-LEVEL INVESTIGATION OF PARTICIPANT AND STUDY PARTNER REPORT ON THE COGNITIVE FUNCTION INDEX FROM THE A4 STUDY SCREENING DATAJ Prev Alz Dis 2021;3(8):257-262481
ESTABLISHING A TRIAL READY COHORT TO ACCELERATE ALZHEIMER’S CLINICAL TRIAL ENROLLMENT AND TREATMENTSJ Prev Alz Dis 2020;4(7):202-203475
TRC-PAD: ACCELERATING RECRUITMENT OF AD CLINICAL TRIALS THROUGH INNOVATIVE INFORMATION TECHNOLOGYJ Prev Alz Dis 2020;4(7):226-233473
LONGITUDINAL COURSE OF AGITATION AND AGGRESSION IN PATIENTS WITH ALZHEIMER’S DISEASE IN A COHORT STUDY: METHODS, BASELINE AND LONGITUDINAL RESULTS OF THE A3C STUDYJ Prev Alz Dis 2021;2(8):199-209420
EDITORIAL: APPROPRIATE USE RECOMMENDATIONS FOR LECANEMABJ Prev Alz Dis 2023;3(10):356401
ALZHEIMER’S DISEASE RESEARCH IN JAPAN: A SHORT HISTORY, CURRENT STATUS AND FUTURE PERSPECTIVES TOWARD PREVENTIONJ Prev Alz Dis 2021;4(8):462-464400
THERAPEUTIC TARGETS FOR ALZHEIMER’S DISEASE: AMYLOID VS. NON-AMYLOID. WHERE DOES CONSENSUS LIE TODAY? AN CTAD TASK FORCE REPORTJ Prev Alz Dis 2022;2(9):231-235386
THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD) – A FUNDAMENTAL ALLY IN AD PREVENTION RESEARCHJ Prev Alz Dis 2020;4(7):206-207382
VIEWPOINT: WHAT IS REASONABLE AND NECESSARY FOR PEOPLE LIVING WITH AD AFTER THE FDA APPROVES A TREATMENT?J Prev Alz Dis 2023;3(10):344-345382
THE COST-EFFECTIVENESS OF THREE PREVENTION STRATEGIES IN ALZHEIMER\'S DISEASE: RESULTS FROM THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL (MAPT)J Prev Alz Dis 2021;4(8):425-435381
PLATFORM TRIALS TO EXPEDITE DRUG DEVELOPMENT IN ALZHEIMER’S DISEASE: A REPORT FROM THE EU/US CTAD TASK FORCEJ Prev Alz Dis 2021;3(8):306-312375
IN VIVO DETECTION OF CHANGES RELATED TO CORTICAL COLUMNAR ORGANIZATION AND NEUROINFLAMMATION ACROSS THE AD CONTINUUMJ Prev Alz Dis 2022;4(9):769-779375
TACKLING A MAJOR DEFICIENCY OF DIVERSITY IN ALZHEIMER’S DISEASE THERAPEUTIC TRIALS: AN CTAD TASK FORCE REPORTJ Prev Alz Dis 2022;3(9):388-392368
DEMENTIA PREVENTION: A GLOBAL CHALLENGE IN URGENT NEED OF SOLUTIONSJ Prev Alz Dis 2022;1(9):1-2366
THE INSTITUTE ON METHODS AND PROTOCOLS FOR ADVANCEMENT OF CLINICAL TRIALS IN ADRD (IMPACT-AD): A NOVEL CLINICAL TRIALS TRAINING PROGRAMJ Prev Alz Dis 2021;3(8):286-291354
CAN VIRTUAL SCIENTIFIC CONFERENCES FACILITATE TWOWAY LEARNING BETWEEN DEMENTIA RESEARCHERS AND PARTICIPANTS?J Prev Alz Dis 2021;3(8):387-388352
MECHANISMS UNDERLYING NON-PHARMACOLOGICAL DEMENTIA PREVENTION STRATEGIES: A TRANSLATIONAL PERSPECTIVEJ Prev Alz Dis 2022;1(9):3-11348
PROTOCOL FOR THE BRAIN HEALTH SUPPORT PROGRAM STUDY OF THE CANADIAN THERAPEUTIC PLATFORM TRIAL FOR MULTIDOMAIN INTERVENTIONS TO PREVENT DEMENTIA (CANTHUMBS UP): A PROSPECTIVE 12-MONTH INTERVENTION STUDYJ Prev Alz Dis 2023;4(10):875-885345
MAJOR COST DRIVERS IN ASSESSING THE ECONOMIC BURDEN OF ALZHEIMER’S DISEASE: A STRUCTURED, RAPID REVIEWJ Prev Alz Dis 2021;3(8):362-370339
DONANEMAB (LY3002813) PHASE 1B STUDY IN ALZHEIMER’S DISEASE: RAPID AND SUSTAINED REDUCTION OF BRAIN AMYLOID MEASURED BY FLORBETAPIR F18 IMAGINGJ Prev Alz Dis 2021;4(8):414-424338
GENDER-SPECIFIC DESIGN AND EFFECTIVENESS OF NONPHARMACOLOGICAL INTERVENTIONS AGAINST COGNITIVE DECLINE – SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALSJ Prev Alz Dis 2023;1(10):69-82338
LECANEMAB CLARITY AD: QUALITY-OF-LIFE RESULTS FROM A RANDOMIZED, DOUBLE-BLIND PHASE 3 TRIAL IN EARLY ALZHEIMER’S DISEASEJ Prev Alz Dis 2023;4(10):771-777335
TRANSLATING THE BIOLOGY OF AGING INTO NEW THERAPEUTICS FOR ALZHEIMER’S DISEASE: SENOLYTICSJ Prev Alz Dis 2023;4(10):633-646333
MULTIMODAL PREVENTIVE TRIAL FOR ALZHEIMER’S DISEASE: MIND-ADMINI PILOT TRIAL STUDY DESIGN AND PROGRESSJ Prev Alz Dis 2022;1(9):30-39329
BLOOD DERIVED AMYLOID BIOMARKERS FOR ALZHEIMER’S DISEASE PREVENTIONJ Prev Alz Dis 2022;1(9):12-21325
COMPARATIVE ANALYSIS OF DIFFERENT DEFINITIONS OF AMYLOID-Β POSITIVITY TO DETECT EARLY DOWNSTREAM PATHOPHYSIOLOGICAL ALTERATIONS IN PRECLINICAL ALZHEIMERJ Prev Alz Dis 2021;1(8):68-77321
DIGITAL THERAPEUTICS FOR MCI AND ALZHEIMER’S DISEASE: A REGULATORY PERSPECTIVE - HIGHLIGHTS FROM THE CLINICAL TRIALS ON ALZHEIMER’S DISEASE CONFERENCE (CTAD)J Prev Alz Dis 2022;2(9):236-240321
ORAL HEALTH AS A RISK FACTOR FOR ALZHEIMER DISEASEJ Prev Alz Dis 2024;1(11):249-258320
THE CRITICAL ROLE OF BIOMARKERS FOR DRUG DEVELOPMENT TARGETING THE BIOLOGY OF AGINGJ Prev Alz Dis 2023;4(10):729-742319
USING DIGITAL TOOLS TO ADVANCE ALZHEIMER’S DRUG TRIALS DURING A PANDEMIC: THE EU/US CTAD TASK FORCEJ Prev Alz Dis 2021;4(8):513-519315
WHAT MATTERS TO PATIENTS WITH ALZHEIMER’S DISEASE AND THEIR CARE PARTNERS? IMPLICATIONS FOR UNDERSTANDING THE VALUE OF FUTURE INTERVENTIONSJ Prev Alz Dis 2022;3(9):550-555315
A UK-WIDE STUDY EMPLOYING NATURAL LANGUAGE PROCESSING TO DETERMINE WHAT MATTERS TO PEOPLE ABOUT BRAIN HEALTH TO IMPROVE DRUG DEVELOPMENT: THE ELECTRONIC PERSON-SPECIFIC OUTCOME MEASURE (EPSOM) PROGRAMMEJ Prev Alz Dis 2021;4(8):448-456314
ADUCANUMAB: APPROPRIATE USE RECOMMENDATIONS UPDATEJ Prev Alz Dis 2022;2(9):221-230313
GEROSCIENCE AND ALZHEIMER’S DISEASE DRUG DEVELOPMENTJ Prev Alz Dis 2023;4(10):620-632312
LONGITUDINAL COGNITIVE DECLINE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT OR DEMENTIA DUE TO ALZHEIMER’S DISEASEJ Prev Alz Dis 2022;1(9):178-183311
NEUROINFLAMMATION, ITS ROLE IN ALZHEIMER’S DISEASE AND THERAPEUTIC STRATEGIESJ Prev Alz Dis 2023;4(10):686-698307
CLINICAL TRIAL ENDPOINTS AND THEIR CLINICAL MEANINGFULNESS IN EARLY STAGES OF ALZHEIMER’S DISEASEJ Prev Alz Dis 2022;3(9):507-522304
THE FUTURE OF AD CLINICAL TRIALS WITH THE ADVENT OF ANTI-AMYLOID THERAPIES: AN CTAD TASK FORCE REPORTJ Prev Alz Dis 2022;3(9):393-399302
MESENCHYMAL STEM CELLS MODULATE SIRT1/MIR-134/ GSK3Β SIGNALING PATHWAY IN A RAT MODEL OF ALZHEIMER\'S DISEASEJ Prev Alz Dis 2022;3(9):458-468301
MODULATION OF MITOCHONDRIAL FUNCTION AS A THERAPEUTIC STRATEGY FOR NEURODEGENERATIVE DISEASESJ Prev Alz Dis 2023;4(10):675-685292
DETECTION AND MANAGEMENT OF AMYLOID-RELATED IMAGING ABNORMALITIES IN PATIENTS WITH ALZHEIMER’S DISEASE TREATED WITH ANTI-AMYLOID BETA THERAPYJ Prev Alz Dis 2022;2(9):211-220291
EDITORIAL: DIETARY CHOLESTEROL AND DEMENTIA RISKJ Prev Alz Dis 2023;4(10):746-747283
BASELINE FINDINGS OF PREVENTE4: A DOUBLE-BLIND PLACEBO CONTROLLED CLINICAL TRIAL TESTING HIGH DOSE DHA IN APOE4 CARRIERS BEFORE THE ONSET OF DEMENTIAJ Prev Alz Dis 2023;4(10):810-820282
THE COMMUNITY ENGAGED DIGITAL ALZHEIMER’S RESEARCH (CEDAR) STUDY: A DIGITAL INTERVENTION TO INCREASE RESEARCH PARTICIPATION OF BLACK AMERICAN PARTICIPANTS IN THE BRAIN HEALTH REGISTRYJ Prev Alz Dis 2023;4(10):847-856280
ESTIMATES OF CURRENT CAPACITY FOR DIAGNOSING ALZHEIMER’S DISEASE IN SWEDEN AND THE NEED TO EXPAND SPECIALIST NUMBERSJ Prev Alz Dis 2024;1(11):155-161271
WHERE DO WE GO FROM HERE?J Prev Alz Dis 2022;2(9):188-189270
ELECSYS CEREBROSPINAL FLUID ASSAYS ACCURATELY DISTINGUISH ALZHEIMER’S DISEASE FROM FRONTOTEMPORAL LOBAR DEGENERATIONJ Prev Alz Dis 2022;3(9):491-498269
DEVELOPMENT OF A MOBILE-FIRST REGISTRY TO RECRUIT HEALTHY VOLUNTEERS AND MEMBERS OF UNDERREPRESENTED COMMUNITIES FOR ALZHEIMER’S DISEASE PREVENTION STUDIESJ Prev Alz Dis 2023;4(10):857-864267
SEX-DRIVEN DIFFERENCES IN THE EFFECTIVENESS OF INDIVIDUALIZED CLINICAL MANAGEMENT OF ALZHEIMER’S DISEASE RISKJ Prev Alz Dis 2022;4(9):731-742265
DECREASED GRAY–WHITE MATTER CONTRAST OF [11C]-PIB UPTAKE IN COGNITIVELY UNIMPAIRED SUBJECTS WITH SEVERE OBSTRUCTIVE SLEEP APNEAJ Prev Alz Dis 2022;3(9):499-506263
AMYLOID-RELATED IMAGING ABNORMALITIES AND OTHER MRI FINDINGS IN A COGNITIVELY UNIMPAIRED POPULATION WITH AND WITHOUT CEREBRAL AMYLOIDJ Prev Alz Dis 2022;4(9):617-624263
THE EFFECT OF MULTIDOMAIN INTERVENTIONS ON GLOBAL COGNITION, SYMPTOMS OF DEPRESSION AND APATHY – A POOLED ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALSJ Prev Alz Dis 2022;1(9):96-103262
EVIDENCE-BASED TOOLS FOR DIETARY ASSESSMENTS IN NUTRITION EPIDEMIOLOGY STUDIES FOR DEMENTIA PREVENTIONJ Prev Alz Dis 2022;1(9):49-53262
SITE READINESS FRAMEWORK TO IMPROVE HEALTH SYSTEM PREPAREDNESS FOR A POTENTIAL NEW ALZHEIMER’S DISEASE TREATMENT PARADIGMJ Prev Alz Dis 2022;3(9):542-549262
ADUCANUMAB TRIALS EMERGE BUT DON’T ENGAGEJ Prev Alz Dis 2022;2(9):193-196262
EDITORIAL: THE DAWN OF A NEW ERA OF ALZHEIMER’S RESEARCH AND DRUG DEVELOPMENTJ Prev Alz Dis 2022;3(9):385-386260
BUNTANETAP, A NOVEL TRANSLATIONAL INHIBITOR OF MULTIPLE NEUROTOXIC PROTEINS, PROVES TO BE SAFE AND PROMISING IN BOTH ALZHEIMER’S AND PARKINSON’S PATIENTSJ Prev Alz Dis 2023;1(10):25-33259
COMPARATIVE EFFICACY, SAFETY, TOLERABILITY, AND EFFECTIVENESS OF ANTIPSYCHOTICS IN THE TREATMENT OF DEMENTIA-RELATED PSYCHOSIS (DRP): A SYSTEMATIC LITERATURE REVIEWJ Prev Alz Dis 2021;4(8):520-533257
FIBRIN-TARGETING IMMUNOTHERAPY FOR DEMENTIAJ Prev Alz Dis 2023;4(10):647-660252
EDITORIAL: THE STATE OF ALZHEIMER’S RESEARCH AND THE PATH FORWARDJ Prev Alz Dis 2023;4(10):617-619249
ARE POPULATION-LEVEL APPROACHES TO DEMENTIA RISK REDUCTION UNDER-RESEARCHED? A RAPID REVIEW OF THE DEMENTIA PREVENTION LITERATUREJ Prev Alz Dis 2024;1(11):241-248248
A CONFORMATIONAL VARIANT OF P53 (U-P53AZ) AS BLOODBASED BIOMARKER FOR THE PREDICTION OF THE ONSET OF SYMPTOMATIC ALZHEIMER’S DISEASEJ Prev Alz Dis 2022;3(9):469-479247
LOW AMINO ACID SCORE OF BREAKFAST IS ASSOCIATED WITH THE INCIDENCE OF COGNITIVE IMPAIRMENT IN OLDER JAPANESE ADULTS: A COMMUNITY-BASED LONGITUDINAL STUDYJ Prev Alz Dis 2022;1(9):151-157245
THE ‘ADUCANUMAB STORY’: WILL THE LAST CHAPTER SPELL THE END OF THE ‘AMYLOID HYPOTHESIS’ OR MARK A NEW BEGINNING?J Prev Alz Dis 2022;2(9):190-192242
ANTI-AMYLOID THERAPIES FOR ALZHEIMER’S DISEASE: AN ALZHEIMER EUROPE POSITION PAPER AND CALL TO ACTIONJ Prev Alz Dis 2024;2(11):265-273240
LECANEMAB: APPROPRIATE USE RECOMMENDATIONSJ Prev Alz Dis 2023;3(10):362-377239
UNSUPERVISED PERFORMANCE OF THE COGSTATE BRIEF BATTERY IN THE BRAIN HEALTH REGISTRY: IMPLICATIONS FOR DETECTING COGNITIVE DECLINEJ Prev Alz Dis 2022;2(9):262-268237
THE SCOTTISH BRAIN HEALTH SERVICE MODEL: RATIONALE AND SCIENTIFIC BASIS FOR A NATIONAL CARE PATHWAY OF BRAIN HEALTH SERVICES IN SCOTLANDJ Prev Alz Dis 2022;2(9):348-358236
SEX MODERATES THE ASSOCIATION BETWEEN FRAILTY AND MILD BEHAVIORAL IMPAIRMENTJ Prev Alz Dis 2022;4(9):692-700232
15th Conference Clinical Trials Alzheimer’s Disease, November 29- December 2, 2022, San Francisco, CA, USAJ Prev Alz Dis 2022;9(S1):S51-S248231
ORAL TAU AGGREGATION INHIBITOR FOR ALZHEIMER’S DISEASE: DESIGN, PROGRESS AND BASIS FOR SELECTION OF THE 16 MG/DAY DOSE IN A PHASE 3, RANDOMIZED, PLACEBOCONTROLLED TRIAL OF HYDROMETHYLTHIONINE MESYLATEJ Prev Alz Dis 2022;4(9):780-790230
ASSOCIATIONS OF CARDIOVASCULAR AND NONCARDIOVASCULAR COMORBIDITIES WITH DEMENTIA RISK IN PATIENTS WITH DIABETES: RESULTS FROM A LARGE UK COHORT STUDYJ Prev Alz Dis 2022;1(9):86-91229
COGNITIVE DIGITAL BIOMARKERS FROM AUTOMATED TRANSCRIPTION OF SPOKEN LANGUAGEJ Prev Alz Dis 2022;4(9):791-800227
MULTIMODAL PRECISION PREVENTION - A NEW DIRECTION IN ALZHEIMER’S DISEASEJ Prev Alz Dis 2023;4(10):718-728224
ASURE CLINICAL TRIAL PROTOCOL: A RANDOMIZED, PLACEBOCONTROLLED, PROOF-OF-CONCEPT STUDY AIMING TO EVALUATE SAFETY AND TARGET ENGAGEMENT FOLLOWING ADMINISTRATION OF TW001 IN EARLY ALZHEIMER’S DISEASE PATIENTSJ Prev Alz Dis 2023;4(10):669-674223
THE USE OF EPISODIC MEMORY TESTS FOR SCREENING IN CLINICAL TRIALS FOR EARLY ALZHEIMER’S DISEASE: A COMPARISON OF THE FREE AND CUED SELECTIVE REMINDING TEST (FCSRT) AND THE REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS (RBANS)J Prev Alz Dis 2023;1(10):41-49222
LIVING ENVIRONMENT, BUILT ENVIRONMENT AND COGNITIVE FUNCTION AMONG OLDER CHINESE ADULTS: RESULTS FROM A CROSS-SECTIONAL STUDYJ Prev Alz Dis 2022;1(9):126-135221
VALIDATION, DEPLOYMENT, AND REAL-WORLD IMPLEMENTATION OF A MODULAR TOOLBOX FOR ALZHEIMER’S DISEASE DETECTION AND DEMENTIA RISK REDUCTION: THE AD-RIDDLE PROJECTJ Prev Alz Dis 2024;2(11):329-338221
INVESTIGATING PARTIALLY DISCORDANT RESULTS IN PHASE 3 STUDIES OF ADUCANUMABJ Prev Alz Dis 2023;2(10):171-177219
OPPORTUNITIES FOR CELLULAR REJUVENATION IN ALZHEIMER’S DISEASE: HOW EPIGENETIC REPROGRAMMING AND CHAPERONE-MEDIATED AUTOPHAGY ARE ENABLING NEXT GENERATION THERAPEUTIC APPROACHESJ Prev Alz Dis 2023;4(10):661-668216
BEYOND VISION: A VIEW FROM EYE TO ALZHEIMER’S DISEASE AND DEMENTIAJ Prev Alz Dis 2024;2(11):469-483215
A POLYMORPHISM CLUSTER AT THE 2Q12 LOCUS MAY PREDICT RESPONSE TO PIROMELATINE IN PATIENTS WITH MILD ALZHEIMER\'S DISEASEJ Prev Alz Dis 2022;2(9):255-261214
VALIDITY OF ONLINE VERSUS IN-CLINIC SELF-REPORTED EVERYDAY COGNITION SCALEJ Prev Alz Dis 2022;2(9):269-276214
BURDEN OF ILLNESS IN PEOPLE WITH ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW OF EPIDEMIOLOGY, COMORBIDITIES AND MORTALITYJ Prev Alz Dis 2024;1(11):97-107213
EDITORIAL: THE FUTURE IS NOW: ADVANCING BLOOD-BASED MARKERSJ Prev Alz Dis 2022;4(9):563-564212
EDITORIAL: WHAT ARE THE REMAINING CHALLENGES BEFORE BLOODBASED BIOMARKERS FOR ALZHEIMER’S DISEASE CAN BE USED IN CLINICAL PRACTICE?J Prev Alz Dis 2022;4(9):567-568210
ESTABLISHING CLINICALLY MEANINGFUL CHANGE ON OUTCOME ASSESSMENTS FREQUENTLY USED IN TRIALS OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASEJ Prev Alz Dis 2023;1(10):9-18208
BLOOD BIOMARKERS FROM RESEARCH USE TO CLINICAL PRACTICE: WHAT MUST BE DONE? A REPORT FROM THE EU/US CTAD TASK FORCEJ Prev Alz Dis 2022;4(9):569-579207
Editorial: Current Themes and Controversies in the Alzheimer’s Disease Field: Looking Ahead to the ctad Meeting in San Francisco, November 29-December 2 2022J Prev Alz Dis 2022;9(S1):S3-S4207
LETTER TO THE EDITOR: BEYOND FRAILTY IN ALZHEIMER’S DISEASE: SHOULD WE MOVE TO THE CONCEPT OF INTRINSIC CAPACITY?J Prev Alz Dis 2022;4(9):813-815206
REDUCING THE EFFECTS OF AGEING ON COGNITION WITH THERAPEUTIC INTERVENTION OF AN ORAL MULTI-NUTRIENT: THE REACTION PILOT TRIAL STUDY DESIGNJ Prev Alz Dis 2023;4(10):821-827206
ACU193, A MONOCLONAL ANTIBODY THAT SELECTIVELY BINDS SOLUBLE ASS OLIGOMERS: DEVELOPMENT RATIONALE, PHASE 1 TRIAL DESIGN, AND CLINICAL DEVELOPMENT PLANJ Prev Alz Dis 2023;1(10):19-24205
EDITORIAL: THE CLINICAL TRIALS ALZHEIMER’S DISEASE (CTAD) MEETING IN SAN FRANCISCO, FALL 2022, WILL BE A VERY EXCITING EVENT!J Prev Alz Dis 2022;3(9):387204
SAFETY, TOLERABILITY, PHARMACOKINETICS AND QUANTITATIVE ELECTROENCEPHALOGRAPHY ASSESSMENT OF ACD856, A NOVEL POSITIVE ALLOSTERIC MODULATOR OF TRK-RECEPTORS FOLLOWING MULTIPLE DOSES IN HEALTHY SUBJECTSJ Prev Alz Dis 2023;4(10):778-789204
TARGETING ENDOGENOUS MECHANISMS OF BRAIN RESILIENCE FOR THE TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASEJ Prev Alz Dis 2023;4(10):699-705204
CONSISTENCY BETWEEN TREATMENT EFFECTS ON CLINICAL AND BRAIN ATROPHY OUTCOMES IN ALZHEIMER’S DISEASE TRIALSJ Prev Alz Dis 2024;1(11):38-47204
EDITORIAL: CLINICAL IMPLEMENTATION OF LECANEMAB: CHALLENGES, QUESTIONS AND SOLUTIONSJ Prev Alz Dis 2023;3(10):353-355199
EDITORIAL: BLOOD-BASED BIOMARKERS FOR ALZHEIMER’S DISEASE: ARE WE THERE YET?J Prev Alz Dis 2022;4(9):565-566197
ADJUDICATING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE AS A NOVEL ENDPOINT EVENT IN THE TOMMORROW PREVENTION CLINICAL TRIALJ Prev Alz Dis 2022;4(9):625-634196
15th Conference Clinical Trials Alzheimer’s Disease, November 29- December 2, 2022, San Francisco, CA, USAJ Prev Alz Dis 2022;9(S1):S8-S50194
EDITORIAL: WHAT IS REASONABLE AND NECESSARY FOR ALZHEIMER PATIENTS FROM RANDOMIZED CLINICAL TRIALS TO CLINICAL PRACTICE?J Prev Alz Dis 2023;3(10):331-332194
HOW MODIFIABLE ARE MODIFIABLE DEMENTIA RISK FACTORS? A FRAMEWORK FOR CONSIDERING THE MODIFIABILITY OF DEMENTIA RISK FACTORSJ Prev Alz Dis 2024;1(11):22-37194
DIAGNOSTIC BIOMARKERS OF AMYLOID AND TAU PATHOLOGY IN ALZHEIMER’S DISEASE: AN OVERVIEW OF TESTS FOR CLINICAL PRACTICE IN THE UNITED STATES AND EUROPEJ Prev Alz Dis 2023;3(10):426-442193
ASSOCIATION OF BLOOD MICRORNA EXPRESSION AND POLYMORPHISMS WITH COGNITIVE AND BIOMARKER CHANGES IN OLDER ADULTSJ Prev Alz Dis 2024;1(11):230-240193
CLINICAL DEVELOPMENT OF ADUCANUMAB, AN ANTI-A? HUMAN MONOCLONAL ANTIBODY BEING INVESTIGATED FOR THE TREATMENT OF EARLY ALZHEIMER’S DISEASEJ Prev Alz Dis 2017;4(4):255-263192
PROTOCOL OF A PHASE II RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF S-ADENOSYL METHIONINE IN PARTICIPANTS WITH MILD COGNITIVE IMPAIRMENT OR DEMENTIA DUE TO ALZHEIMER’S DISEASEJ Prev Alz Dis 2023;4(10):800-809191
DATA-DRIVEN THRESHOLDING STATISTICALLY BIASES ATN PROFILING ACROSS COHORT DATASETSJ Prev Alz Dis 2024;1(11):185-195190
THE GERAS SOLUTIONS COGNITIVE TEST FOR ASSESSING COGNITIVE IMPAIRMENT: NORMATIVE DATA FROM A POPULATION-BASED COHORTJ Prev Alz Dis 2023;2(10):207-211189
COGNITIVE PERFORMANCE AND INCIDENT ALZHEIMER’S DEMENTIA IN MEN VERSUS WOMENJ Prev Alz Dis 2024;1(11):162-170189
THE ROLE OF AΒ IN ALZHEIMER’S DISEASE AS AN EVOLUTIONARY OUTCOME OF OPTIMIZED INNATE IMMUNE DEFENSEJ Prev Alz Dis 2022;4(9):580-588188
PREFERENCES ABOUT FUTURE ALZHEIMER’S DISEASE TREATMENTS ELICITED THROUGH AN ONLINE SURVEY USING THE THRESHOLD TECHNIQUEJ Prev Alz Dis 2023;4(10):756-764184
HEALTH ECONOMIC CONSIDERATIONS IN THE DEPLOYMENT OF AN ALZHEIMER’S PREVENTION THERAPYJ Prev Alz Dis 2024;2(11):303-309183
VIEWPOINT: AMYLOID-TARGETING NEW THERAPIES FOR ALZHEIMER’S DISEASE: A HEALTH ECONOMICS PERSPECTIVEJ Prev Alz Dis 2023;3(10):349-352181
TWO-YEAR PROGNOSTIC UTILITY OF PLASMA P217+TAU ACROSS THE ALZHEIMER’S CONTINUUMJ Prev Alz Dis 2023;4(10):828-836181
EDITORIAL: CHANGE ON CLINICAL TRIAL OUTCOME ASSESSMENTS: THE SEARCH FOR MEANINGFULNESSJ Prev Alz Dis 2023;1(10):5-6178
MODIFIABLE RISK FACTORS FOR ACCELERATED DECLINE IN PROCESSING SPEED: RESULTS FROM THREE DUTCH POPULATION COHORTSJ Prev Alz Dis 2024;1(11):108-116178
EDITORIAL: FAILURE AFTER FAILURE. WHAT NEXT IN AD DRUG DEVELOPMENT?J Prev Alz Dis 2019;6(3):150177
SYSTEMATIC AND COMPARATIVE ANALYSIS OF THE BURDEN OF ALZHEIMER´S DISEASE AND OTHER DEMENTIAS IN MEXICO. RESULTS AT THE NATIONAL AND SUBNATIONAL LEVELS, 1990- 2019J Prev Alz Dis 2023;1(10):120-129177
GLOBAL ENERGY METABOLISM DEFICIT IN ALZHEIMER DISEASE BRAINJ Prev Alz Dis 2024;1(11):171-178177
VIEWPOINT «COMPOUNDED INTEREST» IN ALZHEIMER’S DISEASE: DO NEW AMYLOID-TARGETING TREATMENTS JUSTIFY THEIR USEJ Prev Alz Dis 2023;3(10):333-335174
EDITORIAL: EXPANDING THE ATN FRAMEWORK TO FURTHER PERSONALIZE THERAPIESJ Prev Alz Dis 2023;3(10):380171
UNDERSTANDING BARRIERS AND FACILITATORS TO SIGNING UP FOR A MOBILE-RESPONSIVE REGISTRY TO RECRUIT HEALTHY VOLUNTEERS AND MEMBERS OF UNDERREPRESENTED COMMUNITIES FOR ALZHEIMER’S DISEASE PREVENTION STUDIESJ Prev Alz Dis 2023;4(10):865-874170
ANTIHYPERTENSIVE AGENTS AND INCIDENT ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIESJ Prev Alz Dis 2022;4(9):715-724167
ASSOCIATIONS BETWEEN PARTICIPANT CHARACTERISTICS AND PARTICIPANT FEEDBACK ABOUT AN UNSUPERVISED ONLINE COGNITIVE ASSESSMENT IN A RESEARCH REGISTRYJ Prev Alz Dis 2023;3(10):607-614167
EXPLORING THE ASSOCIATION BETWEEN AMYLOID-Β AND MEMORY MARKERS FOR ALZHEIMER’S DISEASE IN COGNITIVELY UNIMPAIRED OLDER ADULTSJ Prev Alz Dis 2024;2(11):339-347167
EDITORIAL: ACCELERATING INNOVATIONS FOR ENHANCED BRAIN HEALTH. CAN ARTIFICIAL INTELLIGENCE ADVANCE NEW PATHWAYS FOR DRUG DISCOVERY FOR ALZHEIMER’S AND OTHER NEURODEGENERATIVE DISORDERS?J Prev Alz Dis 2023;1(10):1-4166
LETTER TO THE EDITOR: AMBAR: A THERAPEUTICAL APPROACH FOR ALZHEIMER’S DISEASE PATIENTS REGARDLESS OF AMYLOID STATUSJ Prev Alz Dis 2023;1(10):148-149165
PROJECTED SAVINGS TO CANADIAN PROVINCIAL BUDGETS FROM REDUCED LONG-TERM CARE HOME UTILIZATION DUE TO A DISEASE-MODIFYING ALZHEIMER’S TREATMENTJ Prev Alz Dis 2024;1(11):179-184164
VIEWPOINT: BALANCING THE CONFLICTING GOALS FOR TREATMENT OF ALZHEIMER’S DISEASE WITH MONOCLONAL ANTIBODIESJ Prev Alz Dis 2023;3(10):336-338162
UNSUPERVISED ONLINE PAIRED ASSOCIATES LEARNING TASK FROM THE CAMBRIDGE NEUROPSYCHOLOGICAL TEST AUTOMATED BATTERY (CANTAB®) IN THE BRAIN HEALTH REGISTRYJ Prev Alz Dis 2024;2(11):514-524162
DIGITAL CLOCK DRAWING AS AN ALZHEIMER’S DISEASE SUSCEPTIBILITY BIOMARKER: ASSOCIATIONS WITH GENETIC RISK SCORE AND APOE IN OLDER ADULTSJ Prev Alz Dis 2024;1(11):79-87161
EDITORIAL: LECANEMAB: APPROPRIATE USE RECOMMENDATIONS – A COMMENTARY FROM A EUROPEAN PERSPECTIVEJ Prev Alz Dis 2023;3(10):357-358160
CAN WE USE BLOOD BIOMARKERS AS ENTRY CRITERIA AND FOR MONITORING DRUG TREATMENT EFFECTS IN CLINICAL TRIALS? A REPORT FROM THE EU/US CTAD TASK FORCEJ Prev Alz Dis 2023;3(10):418-425160
EDITORIAL: USEFULNESS OF ANCHOR BASED METHODS FOR DETERMINING CLINICALLY MEANINGFUL CHANGE IN MCI DUE TO ADJ Prev Alz Dis 2023;1(10):7-8156
THE ROLE OF THYROID DYSFUNCTION IN ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSISJ Prev Alz Dis 2023;2(10):276-286155
COST-EFFECTIVENESS OF PREVENTION FOR PEOPLE AT RISK FOR DEMENTIA: A SCOPING REVIEW AND QUALITATIVE SYNTHESISJ Prev Alz Dis 2024;2(11):402-413155
OUTREACH, SCREENING, AND RANDOMIZATION OF APOE Ε4 CARRIERS INTO AN ALZHEIMER’S PREVENTION TRIAL: A GLOBAL PERSPECTIVE FROM THE API GENERATION PROGRAMJ Prev Alz Dis 2023;3(10):453-463152
CROSS-SECTIONAL AND LONGITUDINAL COMPARISON OF TAU IMAGING WITH 18F-MK6240 AND 18F-FLORTAUCIPIR IN POPULATIONS MATCHED FOR AGE, MMSE AND BRAIN BETA-AMYLOID BURDENJ Prev Alz Dis 2023;2(10):251-258151
A PHASE 1 SINGLE-ASCENDING-DOSE TRIAL IN HEALTHY VOLUNTEERS TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF INTRAVENOUS PNT001, A NOVEL MID-DOMAIN TAU ANTIBODY TARGETING CIS-PT231 TAUJ Prev Alz Dis 2024;2(11):366-374151
EDUCATION AS RISK FACTOR OF MILD COGNITIVE IMPAIRMENT: THE LINK TO THE GUT MICROBIOMEJ Prev Alz Dis 2024;3(11):759-768150
UTILITY OF ENVIRONMENTAL COMPLEXITY AS A PREDICTOR OF ALZHEIMER’S DISEASE DIAGNOSIS: A BIG-DATA MACHINE LEARNING APPROACHJ Prev Alz Dis 2023;2(10):223-235149
PREDICTING PROGRESSION FROM NORMAL TO MCI AND FROM MCI TO AD USING CLINICAL VARIABLES IN THE NATIONAL ALZHEIMER’S COORDINATING CENTER UNIFORM DATA SET VERSION 3: APPLICATION OF MACHINE LEARNING MODELS AND A PROBABILITY CALCULATORJ Prev Alz Dis 2023;2(10):301-313149
VORTIOXETINE TREATMENT FOR DEPRESSION IN PATIENTS WITH PRODROMAL VS MILD ALZHEIMER’S DISEASE: A SIXMONTH, OPEN-LABEL, OBSERVATIONAL STUDYJ Prev Alz Dis 2024;2(11):375-381149
VIEWPOINT: CLINICIANS’ PERSPECTIVES ON HOW DISEASE MODIFYING DRUGS FOR ALZHEIMER’S DISEASE IMPACT SPECIALTY CAREJ Prev Alz Dis 2023;3(10):339-341147
COMMENTARY: CLINICAL EFFICACY IN INDIVIDUAL PATIENTS TREATED WITH LECANEMABJ Prev Alz Dis 2023;3(10):378-379143
PUSHING THROUGH THE BARRIERS: PEER ADVICE TO INCREASE PHYSICAL ACTIVITY AND REDUCE DEMENTIA RISK FROM PARTICIPANTS IN A MASSIVE OPEN ONLINE ALZHEIMER’S FOCUSED COURSEJ Prev Alz Dis 2023;3(10):503-512143
COMBINED EVIDENCE FOR A LONG-TERM, CLINICAL SLOWING EFFECT OF MULTINUTRIENT INTERVENTION IN PRODROMAL ALZHEIMER’S DISEASE: POST-HOC ANALYSIS OF 3-YEAR DATA FROM THE LIPIDIDIET TRIALJ Prev Alz Dis 2023;3(10):464-470142
‘TIME SAVED’ AS A DEMONSTRATION OF CLINICAL MEANINGFULNESS AND ILLUSTRATED USING THE DONANEMAB TRAILBLAZER-ALZ STUDY FINDINGSJ Prev Alz Dis 2023;3(10):595-599142
UNDERSTANDING ONLINE REGISTRY FACILITATORS AND BARRIERS EXPERIENCED BY BLACK BRAIN HEALTH REGISTRY PARTICIPANTS: THE COMMUNITY ENGAGED DIGITAL ALZHEIMER’S RESEARCH (CEDAR) STUDYJ Prev Alz Dis 2023;3(10):551-561140
EDITORIAL: IMPLICATIONS OF EMERGING USES OF GENETIC TESTING FOR ALZHEIMER’S DISEASEJ Prev Alz Dis 2023;3(10):359-361138
ASSOCIATION BETWEEN NEUROPSYCHOLOGICAL PERFORMANCE AND CSF PROFILE IN SUBJECTIVE COGNITIVE DECLINE: TOWARDS THE DIAGNOSIS OF PRECLINICAL ADJ Prev Alz Dis 2023;3(10):523-529137
VIEWPOINT: DEFINING FDA APPROVED TREATMENTS AS REASONABLE AND NECESSARY: PERSPECTIVES OF INDIVIDUALS LIVING WITH ALZHEIMER’S DISEASE AND CARE PARTNERSJ Prev Alz Dis 2023;3(10):346-348132
COHORT EFFECTS IN ALZHEIMER’S DISEASE TRIALS: AN EMPIRICAL ASSESSMENT UTILIZING DATA FROM THE ALZHEIMER’S DISEASE COOPERATIVE STUDYJ Prev Alz Dis 2023;3(10):471-477130
NEUROPROTECTIVE EFFECTS OF IVIG AGAINST ALZHEIMER’ S DISEASE VIA REGULATION OF ANTIGEN PROCESSING AND PRESENTATION BY MHC CLASS I MOLECULES IN 3XTG-AD MICEJ Prev Alz Dis 2023;3(10):581-594128
VALIDATION OF THE COGDRISK INSTRUMENT AS PREDICTIVE OF DEMENTIA IN FOUR GENERAL COMMUNITY-DWELLING POPULATIONSJ Prev Alz Dis 2023;3(10):478-487126
DEVELOPING DISEASE-MODIFYING TREATMENTS IN ALZHEIMER’S DISEASE – A PERSPECTIVE FROM ROCHE AND GENENTECHJ Prev Alz Dis 2017;4(4):264-272124
MULTIOMICS BLOOD-BASED BIOMARKERS PREDICT ALZHEIMER’S PREDEMENTIA WITH HIGH SPECIFICITY IN A MULTICENTRIC COHORT STUDYJ Prev Alz Dis 2024;3(11):567-581123
Editorial: We Have Turned the CornerJ Prev Alz Dis 2022;9(S1):S5-S6120
“TIME SAVED” CALCULATIONS TO IMPROVE DECISION-MAKING IN PROGRESSIVE DISEASE STUDIESJ Prev Alz Dis 2024;3(11):529-536119
WHO BENEFITED THE MOST? EFFECTIVENESS OF A LIFESTYLE INTERVENTION AGAINST COGNITIVE DECLINE IN OLDER WOMEN AND MEN – SECONDARY ANALYSIS OF THE AGEWELL. DE-TRIALJ Prev Alz Dis 2024;2(11):348-355114
ESTIMATED INVESTMENT NEED TO INCREASE ENGLAND’S CAPACITY TO DIAGNOSE ELIGIBILITY FOR AN ALZHEIMER’S TREATMENT TO G7 AVERAGE CAPACITY LEVELS111
24-HOUR BLOOD PRESSURE VARIABILITY VIA AMBULATORY MONITORING AND RISK FOR PROBABLE DEMENTIA IN THE SPRINT TRIALJ Prev Alz Dis 2024;3(11):684-692104
COMPUTERIZED COGNITIVE TRAINING IN MILD COGNITIVE IMPAIRMENT: FINDINGS IN AFRICAN AMERICANS AND CAUCASIANSJ Prev Alz Dis 2024;1(11):149-154101
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERSJ Prev Alz Dis 2017;4(4):282-428100
ERRATUM TO: DIGITAL CLOCK DRAWING AS AN ALZHEIMER’S DISEASE SUSCEPTIBILITY BIOMARKER: ASSOCIATIONS WITH GENETIC RISK SCORE AND APOE IN OLDER ADULTSJ Prev Alz Dis 2024;1(11):26399
DETECTION RATES OF MILD COGNITIVE IMPAIRMENT IN PRIMARY CARE FOR THE UNITED STATES MEDICARE POPULATIONJ Prev Alz Dis 2024;1(11):7-1298
PHASE 2A LEARNINGS INCORPORATED INTO REWIND-LB, A PHASE 2B CLINICAL TRIAL OF NEFLAMAPIMOD IN DEMENTIA WITH LEWY BODIESJ Prev Alz Dis 2024;3(11):549-55794
THE EFFECTS OF DIFFERENT EXERCISE INTERVENTIONS ON PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSISJ Prev Alz Dis 2024;3(11):620-63187
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERSJ Prev Alz Dis 2018;5(S1):S1-S19686
COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCEJ Prev Alz Dis 2019;6(3):164-16886
DEVELOPMENT REVIEW OF THE BACE1 INHIBITOR LANABECESTAT (AZD3293/LY3314814)J Prev Alz Dis 2017;4(4):247-25485
EDITORIAL: TAU BASED THERAPEUTICS: ALTERNATIVE APPROACHES IN THE WAR ON ALZHEIMER’S DISEASEJ Prev Alz Dis 2019;6(3):151-15282
THE 2018 REVISED FDA GUIDANCE FOR EARLY ALZHEIMER’S DISEASE: ESTABLISHING THE MEANINGFULNESS OF TREATMENT EFFECTSJ Prev Alz Dis 2019;6(4):223-22781
WHAT WE LEARN FROM THE CTAD 2018 (CLINICAL TRIALS ALZHEIMER’S DISEASE)J Prev Alz Dis 2018;5(4):214-21580
TREATMENT EFFECTS OF VORTIOXETINE ON COGNITIVE FUNCTIONS IN MILD ALZHEIMER’S DISEASE PATIENTS WITH DEPRESSIVE SYMPTOMS: A 12 MONTH, OPEN-LABEL, OBSERVATIONAL STUDYJ Prev Alz Dis 2019;6(3):192-19778
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERSJ Prev Alz Dis 2014;1(3):214-29675
EDITORIAL: IS NOW THE TIME FOR COMBINATION THERAPIES FOR ALZHEIMER DISEASE?J Prev Alz Dis 2019;6(3):153-15475
EDITORIAL: BLOOD TESTS FOR ALZHEIMER’S DISEASE AND RELATED DISORDERSJ Prev Alz Dis 2019;6(3):155-15670
WHO BENEFITED MOST FROM THE INTERNET-BASED CONVERSATIONAL ENGAGEMENT RCT (I-CONECT)? APPLICATION OF THE PERSONALIZED MEDICINE APPROACH TO A BEHAVIORAL INTERVENTION STUDYJ Prev Alz Dis 2024;3(11):639-64870
LONGITUDINAL IMPACTS OF PRECISION GREENNESS ON ALZHEIMER’S DISEASEJ Prev Alz Dis 2024;3(11):710-72068
DETECTING TREATMENT GROUP DIFFERENCES IN ALZHEIMER’S DISEASE CLINICAL TRIALS: A COMPARISON OF ALZHEIMER’S DISEASE ASSESSMENT SCALE - COGNITIVE SUBSCALE (ADAS-COG) AND THE CLINICAL DEMENTIA RATING - SUM OF BOXES (CDR-SB)J Prev Alz Dis 2018;5(1):15-2067
BIOMARKER AND CLINICAL TRIAL DESIGN SUPPORT FOR DISEASE-MODIFYING THERAPIES: REPORT OF A SURVEY OF THE EU/US: ALZHEIMER’S DISEASE TASK FORCEJ Prev Alz Dis 2018;5(2):103-10964
PROGRESS IN TREATMENT DEVELOPMENT FOR NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER’S DISEASE: FOCUS ON AGITATION AND AGGRESSION. A REPORT FROM THE EU/US/CTAD TASK FORCEJ Prev Alz Dis 2015;2(3):184-18858
TRAJECTORY OF THE MAPT-PACC-PRECLINICAL ALZHEIMER COGNITIVE COMPOSITE IN THE PLACEBO GROUP OF A RANDOMIZED CONTROL TRIAL: RESULTS FROM THE MAPT STUDY: LESSONS FOR FURTHER TRIALSJ Prev Alz Dis 2018;5(1):31-3558
COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCEJ Prev Alz Dis 2019;6(3):180-18154
DELAYED-START ANALYSES IN THE PHASE 3 SOLANEZUMAB EXPEDITION3 STUDY IN MILD ALZHEIMER’S DISEASEJ Prev Alz Dis 2018;5(1):8-1452
COGNITIVE TRAINING WITH OLDER ADULTS USING SMARTPHONE AND WEB-BASED APPLICATIONS: A SCOPING REVIEWJ Prev Alz Dis 2024;3(11):693-70052
ASSOCIATION OF COGNITIVE RESERVE INDICATOR WITH COGNITIVE DECLINE AND STRUCTURAL BRAIN DIFFERENCES IN MIDDLE AND OLDER AGE: FINDINGS FROM THE UK BIOBANKJ Prev Alz Dis 2024;3(11):739-74851
THE ROAD AHEAD TO CURE ALZHEIMER\'S DISEASE: DEVELOPMENT OF BIOLOGICAL MARKERS AND NEUROIMAGING METHODS FOR PREVENTION TRIALS ACROSS ALL STAGES AND TARGET POPULATIONSJ Prev Alz Dis 2014;1(3):181-20250
A KETO-MEDIET APPROACH WITH COCONUT SUBSTITUTION AND EXERCISE MAY DELAY THE ONSET OF ALZHEIMER’S DISEASE AMONG MIDDLE-AGED J Prev Alz Dis 2017;4(1):51-5749
ADVANCING ALZHEIMER’S DISEASE TREATMENT: LESSONS FROM CTAD 2018J Prev Alz Dis 2019;6(3):198-20349
CONTINUING PROGRESS IN ALZHEIMER’S DISEASE TRIALS: CAUSE FOR OPTIMISMJ Prev Alz Dis 2017;4(4):211-21248
COMMENTARY: DEVELOPMENT OF THE BLOOD-BASED ALZHEIMER’S DISEASE LIQUID BIOPSYJ Prev Alz Dis 2019;6(3):182-18448
RESULTS FROM A PHASE II STUDY TO ASSESS THE CLINICAL AND IMMUNOLOGICAL ACTIVITY OF AFFITOPE® AD02 IN PATIENTS WITH EARLY ALZHEIMER’S DISEASEJ Prev Alz Dis 2015;2(2):103-11447
OVERSIMPLIFICATION OF DEMENTIA RISK REDUCTION MESSAGING IS A THREAT TO KNOWLEDGE TRANSLATION IN DEMENTIA PREVENTION RESEARCHJ Prev Alz Dis 2018;5(1):2-447
PLASMA BIOMARKER FOR ALZHEIMER’S DISEASE: ARE WE READY NOW FOR CLINICAL PRACTICE AND DRUG TRIALS?J Prev Alz Dis 2018;5(3):158-15947
MACHINE LEARNING ALGORITHM HELPS IDENTIFY NONDIAGNOSED PRODROMAL ALZHEIMER’S DISEASE PATIENTS IN THE GENERAL POPULATIONJ Prev Alz Dis 2019;6(3):185-19147
ACTIVE IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE: THE ROAD AHEADJ Prev Alz Dis 2015;2(2):78-7946
ERRATUM TO: EDUCATION AS RISK FACTOR OF MILD COGNITIVE IMPAIRMENT: THE LINK TO THE GUT MICROBIOMEJ Prev Alz Dis 2024;3(11):79846
IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVEDJ Prev Alz Dis 2014;1(1):40-4545
A RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF THE EFFECTS OF THE VACCINE VANUTIDE CRIDIFICAR WITH QS-21 ADJUVANT ON IMMUNOGENICITY, SAFETY AND AMYLOID IMAGING IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASEJ Prev Alz Dis 2016;3(4):192-20145
ASSESSMENT OF CLINICAL MEANINGFULNESS OF ENDPOINTS IN THE GENERATION PROGRAM BY THE INSIGHTS TO MODEL ALZHEIMER’S PROGRESSION IN REAL LIFE (IMAP) STUDYJ Prev Alz Dis 2019;6(2):85-8945
E.U./U.S. CTAD TASK FORCE ON ALZHEIMER\'S TRIAL POPULATIONS J Prev Alz Dis 2014;1(2):110-11643
LONGITUDINAL TRAJECTORIES OF CLINICAL DECLINE IN AMYLOID POSITIVE AND NEGATIVE POPULATIONSJ Prev Alz Dis 2016;3(2):92-10043
GLOBAL ALZHEIMER’S PLATFORM TRIAL READY COHORTS FOR THE PREVENTION OF ALZHEIMER’S DEMENTIA J Prev Alz Dis 2016;3(4):185-18743
COMMENTARY: TREATING ALZHEIMER’S DISEASE : COMBINE OR FAIL ?J Prev Alz Dis 2019;6(3):174-17643
COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER’S DISEASE – THE NEXT STEPJ Prev Alz Dis 2019;6(3):17943
DRUG DEVELOPMENT IN AD: POINT OF VIEW FROM THE INDUSTRYJ Prev Alz Dis 2015;2(4):216-21841
UPDATE ON PREVENTION TRIALS IN ALZHEIMER’S DISEASEJ Prev Alz Dis 2014;1(3):168-17540
VANUTIDE CRIDIFICAR (ACC-001) AND QS-21 ADJUVANT IN INDIVIDUALS WITH EARLY ALZHEIMER’S DISEASE: AMYLOID IMAGING POSITRON EMISSION TOMOGRAPHY AND SAFETY RESULTS FROM A PHASE 2 STUDYJ Prev Alz Dis 2016;3(2):75-8440
ESTABLISHING COMPOSITE COGNITIVE ENDPOINTS FOR USE IN PRECLINICAL ALZHEIMER’S DISEASE TRIALSJ Prev Alz Dis 2015;2(1):2-339
RECRUITMENT OF AT-RISK PARTICIPANTS FOR CLINICAL TRIALS: A MAJOR PARADIGM SHIFT FOR ALZHEIMER’S DISEASE PREVENTIONJ Prev Alz Dis 2017;4(4):213-21439
THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS) FINDINGS FROM THE EXPEDITION3 TRIALJ Prev Alz Dis 2018;5(2):134-13639
THE ROAD AHEAD TO CURE AND PREVENT ALZHEIMER’S DISEASE: IMPLEMENTING PREVENTION INTO PRIMARY CAREJ Prev Alz Dis 2015;2(3):199-21138
EXAMINING DEMOGRAPHIC FACTORS, PSYCHOSOCIAL WELLBEING AND CARDIOVASCULAR HEALTH IN SUBJECTIVE COGNITIVE DECLINE IN THE BRAIN HEALTH REGISTRY COHORTJ Prev Alz Dis 2024;3(11):787-79738
PREVENTION: HOW THE PARADIGM IS SHIFTINGJ Prev Alz Dis 2014;1(1):51-5537
COMMENTARY: OPPORTUNITIES FOR COMBINATION TRIALSJ Prev Alz Dis 2019;6(3):177-17837
EDITORIAL: JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE (JPAD): BUILDING A “FLEET” AGAINST ALZHEIMER’S DISEASEJ Prev Alz Dis 2014;1(1):2-336
PRIMARY PREVENTION OF DEMENTIA: THE FUTURE OF POPULATION-BASED MULTIDOMAIN LIFESTYLE INTERVENTIONSJ Prev Alz Dis 2018;5(1):5-736
PRECISION MEDICINE - THE GOLDEN GATE FOR DETECTION, TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASEJ Prev Alz Dis 2016;3(4):243-25935
FACEHBI: A PROSPECTIVE STUDY OF RISK FACTORS, BIOMARKERS AND COGNITION IN A COHORT OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. STUDY RATIONALE AND RESEARCH PROTOCOLSJ Prev Alz Dis 2017;4(2):100-10835
NEUROPSYCHIATRIC SYMPTOMS IN DEMENTIA: OVERVIEW AND MEASUREMENT CHALLENGESJ Prev Alz Dis 2015;2(3):155-15634
HEALTHYBRAINS.ORG: FROM REGISTRY TO RANDOMIZATIONJ Prev Alz Dis 2016;3(3):123-12634
GETTING MORE CLINICALLY MEANINGFUL MEASURES OF FUNCTIONAL IMPAIRMENT FOR ALZHEIMER’S DISEASEJ Prev Alz Dis 2017;4(2):67-6834
EDITORIAL : DEMENTIA PREVENTION STRATEGIES – BEYOND THE RANDOMIZED CONTROLLED TRIAL?J Prev Alz Dis 2014;1(2):62-6433
INTERVENTIONS TO PREVENT COGNITIVE DECLINE AND DEMENTIA IN ADULTS WITHOUT COGNITIVE IMPAIRMENT: A SYSTEMATIC REVIEWJ Prev Alz Dis 2015;2(1):38-4533
METHODOLOGICAL ASPECTS OF THE PHASE II STUDY AFF006 EVALUATING AMYLOID-BETA -TARGETING VACCINE AFFITOPE® AD02 IN EARLY ALZHEIMER’S DISEASE – PROSPECTIVE USE OF NOVEL COMPOSITE SCALESJ Prev Alz Dis 2015;2(2):91-10233
BEYOND THE CONTROVERSY ON Aß BLOOD-BASED BIOMARKERSJ Prev Alz Dis 2015;2(1):51-5532
TRIAL DESIGN FOR THE EVALUATION OF NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER’S DISEASE: CONSIDERATIONS AND RECOMMENDATIONSJ Prev Alz Dis 2015;2(3):163-16432
AT A CROSSROADS: A PERSPECTIVE ON DRUG DEVELOPMENT FOR ALZHEIMER’S DISEASE IN 2016 J Prev Alz Dis 2016;3(4):181-18431
PROSPECTIVE EVALUATION OF COGNITIVE HEALTH AND RELATED FACTORS IN ELDERLY AT RISK FOR DEVELOPING ALZHEIMER’S DEMENTIA: A LONGITUDINAL COHORT STUDYJ Prev Alz Dis 2019;6(4):256-26631
EDITORIAL : THE BRAINHEALTHREGISTRY.ORG: USING THE INTERNET FOR IDENTIFICATION, ASSESSMENT, SCREENING, RECRUITMENT, AND LONGITUDINAL MONITORING OF SUBJECTS FOR NEUROSCIENCE AND ALZHEIMER’S DISEASE STUJ Prev Alz Dis 2014;1(2):59-6130
PRIMARY PREVENTION OF DEMENTIA: AN EPIDEMIOLOGICAL POINT OF VIEWJ Prev Alz Dis 2016;3(3):160-16330
CTAD 2016 abstract: EXPEDITION3: A PHASE 3 TRIAL OF SOLANEZUMAB IN MILD DEMENTIA DUE TO ALZHEIMER’S DISEASE30
EFFECTS OF OMEGA-3 FATTY ACIDS ON RESTING CEREBRAL PERFUSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: A RANDOMIZED CONTROLLED TRIALJ Prev Alz Dis 2018;5(1):26-3030
IS A LARGE-SCALE SCREENING FOR ALZHEIMER’S DISEASE POSSIBLE? YES, IN A FEW YEARSJ Prev Alz Dis 2019;6(4):221-22230
RANDOMIZED, PLACEBO CONTROLLED TRIAL OF NPT088, A PHAGE-DERIVED, AMYLOID-TARGETED TREATMENT FOR ALZHEIMER’S DISEASEJ Prev Alz Dis 2019;6(4):228-23130
EDITORIAL : MULTI-DOMAIN PREVENTION FOR A MULTI-FACTORIAL DISEASEJ Prev Alz Dis 2014;1(1):4-529
THE FEASIBILITY OF AT-HOME IPAD COGNITIVE TESTING FOR USE IN CLINICAL TRIALSJ Prev Alz Dis 2016;3(1):8-1229
PHYSICAL ACTIVITY AND ß-AMYLOID BRAIN LEVELS IN HUMANS: A SYSTEMATIC REVIEWJ Prev Alz Dis 2015;2(1):56-6328
COMMENT : A NEW ERA: DISEASE MODIFYING ALZHEIMER DISEASE PREVENTION TRIALS J Prev Alz Dis 2014;1(2):6828
STUDIES OF AGITATION / AGGRESSION IN ALZHEIMER’S DISEASE – SCIENTIFIC AND OPERATIONAL CHALLENGESJ Prev Alz Dis 2015;2(3):157-15928
DIETARY FACTORS AND COGNITIVE DECLINEJ Prev Alz Dis 2016;3(1):53-6428
LESSONS TO BE LEARNED ABOUT CLINICAL TRIALS IN PRECLINICAL AD FROM ONGOING LONGITUDINAL STUDIESJ Prev Alz Dis 2015;2(4):214-21528
PREVENTION OF ALZHEIMER’S DISEASE IN CHINESE POPULATIONS: STATUS, CHALLENGES AND DIRECTIONSJ Prev Alz Dis 2018;5(2):90-9428
MINIMIZING THE SAMPLE SIZES OF CLINICAL TRIALS ON PRECLINICAL AND EARLY SYMPTOMATIC STAGE OF ALZHEIMER DISEASEJ Prev Alz Dis 2018;5(2):110-11928
A LITERATURE REVIEW OF METHODOLOGIES USED IN RANDOMIZED CLINICAL TRIALS OF AGITATION IN ALZHEIMER’S DISEASEJ Prev Alz Dis 2018;5(2):120-13328
COMMENT: IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVED J Prev Alz Dis 2014;1(1):8-1027
BLOOD-BRAIN BARRIER PERMEABILITY IN AGING AND ALZHEIMER’S DISEASEJ Prev Alz Dis 2014;1(3):138-14027
AMYLOID AND TAU BIOMARKERS IN CSFJ Prev Alz Dis 2015;2(1):46-5027
INVESTIGATING FUNCTIONAL IMPAIRMENT IN PRECLINICAL ALZHEIMER’S DISEASEJ Prev Alz Dis 2015;2(1):4-627
MRI FOR PRE-DEMENTIA TRIALSJ Prev Alz Dis 2016;3(1):5-727
DEVELOPMENT OF AZELIRAGON, AN ORAL SMALL MOLECULE ANTAGONIST OF THE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS, FOR THE POTENTIAL SLOWING OF LOSS OF COGNITION IN MILD ALZHEIMER’S DISEASEJ Prev Alz Dis 2018;5(2):149-15426
CLINICAL APPLICATION OF APOE IN ALZHEIMER’S PREVENTION: A PRECISION MEDICINE APPROACHJ Prev Alz Dis 2018;5(4):245-25226
LONGITUDINAL COMPARISON OF IN CLINIC AND AT HOME ADMINISTRATION OF THE COGSTATE BRIEF BATTERY AND DEMONSTRATED PRACTICE EFFECTS IN THE MAYO CLINIC STUDY OF AGINGJ Prev Alz Dis 2020;7(1):21-2826
COMMENT: IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVED?J Prev Alz Dis 2014;1(1):6-725
BASELINE SUBJECTIVE MEMORY COMPLAINTS ASSOCIATE WITH INCREASED RISK OF INCIDENT DEMENTIA: THE PREADVISE TRIALJ Prev Alz Dis 2015;2(1):11-1625
IMMUNOTHERAPY OF AD: ALUM DEMAIN?J Prev Alz Dis 2015;2(2):80-8125
COMPUTERIZED COGNITIVE TESTING FOR USE IN CLINICAL TRIALS: A COMPARISON OF THE NIH TOOLBOX AND COGSTATE C3 BATTERIESJ Prev Alz Dis 2017;4(1):3-1125
REVISITING THE CHOLINERGIC HYPOTHESIS IN ALZHEIMER’S DISEASE: EMERGING EVIDENCE FROM TRANSLATIONAL AND CLINICAL RESEARCHJ Prev Alz Dis 2019;6(1):2-1525
FACTORS ASSOCIATED WITH ALZHEIMER’S DISEASE: AN OVERVIEW OF REVIEWSJ Prev Alz Dis 2019;6(2):121-13425
“BACK TO BRAAK”: ROLE OF NUCLEUS REUNIENS AND SUBCORTICAL PATHWAYS IN ALZHEIMER’S DISEASE PROGRESSION25
NEW IPA CRITERIA FOR AGITATION IN COGNITIVE IMPAIRMENTJ Prev Alz Dis 2015;2(3):160-16224
BARRIERS FOR PREVENTION AND PRODROMAL AD TRIALSJ Prev Alz Dis 2016;3(2):66-6724
TURNING POINT TOWARDS BLOOD BIOMARKER-GUIDED TARGETED THERAPY FOR PRECISION MEDICINE IN ALZHEIMER’S DISEASEJ Prev Alz Dis 2018;5(3):160-16424
IMPACT OF DIETARY FACTORS AND INFLAMMATION ON COGNITION AMONG OLDER ADULTSJ Prev Alz Dis 2015;2(4):220-22623
WEB-BASED SOFTWARE FOR REAL-TIME SIMULATION-ASSISTED TRIAL DESIGN IN ALZHEIMER’S DISEASEJ Prev Alz Dis 2016;3(1):20-2323
TEA FOR ALZHEIMER PREVENTIONJ Prev Alz Dis 2015;2(2):136-14123
SELF-REPORTED MEMORY COMPLAINTS: A COMPARISON OF DEMENTED AND UNIMPAIRED OUTCOMESJ Prev Alz Dis 2016;3(1):13-1923
THE VALUE OF PRE-SCREENING IN THE ALZHEIMER’S PREVENTION INITIATIVE (API) AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE TRIALJ Prev Alz Dis 2018;5(1):49-5423
ALZHEIMER’S PREVENTION EDUCATION: IF WE BUILD IT, WILL THEY COME? www.AlzU.orgJ Prev Alz Dis 2014;1(2):91-9822
COMMENT : ALZHEIMER’S DISEASE DRUG DEVELOPMENT: TRIAL-READY COHORTS SHOULD HELPJ Prev Alz Dis 2014;1(2):69-7022
ALZHEIMER’S DISEASE PREVENTION: REALITY OR UTOPIA?J Prev Alz Dis 2014;1(3):141-14222
FOREWORD: AD DRUG DEVELOPMENT IS NOT BROKEN: CLINICAL TRIALS IN ALZHEIMER’S DISEASE 2014 CONFERENCE, PHILADELPHIAJ Prev Alz Dis 2014;1(3):212-21322
COGNITIVE REHABILITATION IN ALZHEIMER’S DISEASE – A CONCEPTUAL AND METHODOLOGICAL REVIEWJ Prev Alz Dis 2015;2(2):142-15222
DEMENTIA PREVENTION BY DISEASE-MODIFICATION THROUGH NUTRITIONJ Prev Alz Dis 2017;4(3):138-13922
A NOVEL STUDY PARADIGM FOR LONG-TERM PREVENTION TRIALS IN ALZHEIMER DISEASE: THE PLACEBO GROUP SIMULATION APPROACH (PGSA). APPLICATION TO MCI DATA FROM THE NACC DATABASEJ Prev Alz Dis 2014;1(2):99-10921
DEMENTIA PREVENTION: OPTIMIZING THE USE OF OBSERVATIONAL DATA FOR PERSONAL, CLINICAL, AND PUBLIC HEALTH DECISION-MAKING J Prev Alz Dis 2014;1(2):117-12321
ALZHEIMER’S ASSOCIATION: INITIATIVES & PUBLIC HEALTH PERSPECTIVEJ Prev Alz Dis 2016;3(4):178-18021
ALBUMIN, HEMOGLOBIN, AND THE TRAJECTORY OF COGNITIVE FUNCTION IN COMMUNITY-DWELLING OLDER JAPANESE: A 13-YEAR LONGITUDINAL STUDY J Prev Alz Dis 2017;4(2):93-9921
ADHERENCE TO THE MEDITERRANEAN DIET IS NOT RELATED TO BETA-AMYLOID DEPOSITION: DATA FROM THE WOMEN’S HEALTHY AGEING PROJECTJ Prev Alz Dis 2018;5(2):137-14121
PTI-125 REDUCES BIOMARKERS OF ALZHEIMER’S DISEASE IN PATIENTSJ Prev Alz Dis 2020;4(7):256-26421
COMMENT : E.U./U.S. CTAD TASK FORCE ON ALZHEIMER\'S TRIAL POPULATIONS FOR STUDY J Prev Alz Dis 2014;1(2):66-6720
A PATIENT-CENTERED ANALYSIS OF ENROLLMENT AND RETENTION IN A RANDOMIZED BEHAVIORAL TRIAL OF TWO COGNITIVE REHABILITATION INTERVENTIONS FOR MILD COGNITIVE IMPAIRMENTJ Prev Alz Dis 2014;1(3):143-15020
ASSESSMENT OF AGE-RELATED DIFFERENCES IN FUNCTIONAL CAPACITY USING THE VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT TOOL (VRFCAT)J Prev Alz Dis 2015;2(2):121-12720
THE HARVARD AUTOMATED PHONE TASK: NEW PERFORMANCE-BASED ACTIVITIES OF DAILY LIVING TESTS FOR EARLY ALZHEIMER’S DISEASE J Prev Alz Dis 2015;2(4):242-25320
GINKGO BILOBA EXTRACT CONSUMPTION AND LONG-TERM OCCURRENCE OF DEATH AND DEMENTIAJ Prev Alz Dis 2017;4(1):16-2020
ARIZONA ALZHEIMER’S REGISTRY: STRATEGY AND OUTCOMES OF A STATEWIDE RESEARCH RECRUITMENT REGISTRY J Prev Alz Dis 2014;1(2):74-7919
COMMUNITY-BASED INTERVENTION FOR PREVENTION OF DEMENTIA IN JAPANJ Prev Alz Dis 2015;2(1):71-7619
COSTS AND RESOURCE USE ASSOCIATED WITH ALZHEIMER’S DISEASE IN ITALY: RESULTS FROM AN OBSERVATIONAL STUDYJ Prev Alz Dis 2018;5(1):55-6419
PLASMA A?42/40 RATIO DETECTS EARLY STAGES OF ALZHEIMER’S DISEASE AND CORRELATES WITH CSF AND NEUROIMAGING BIOMARKERS IN THE AB255 STUDYJ Prev Alz Dis 2019;6(1):34-4119
THINKING ABOUT COGNITIVE FRAILTYJ Prev Alz Dis 2015;2(1):7-1018
AN OPEN-LABEL TRIAL OF YOKUKANSAN ON SLEEP DISTURBANCE IN ALZHEIMER’S DISEASE AND OTHER DEMENTIAJ Prev Alz Dis 2015;2(3):172-17718
A NOVEL EIGENVECTOR-BASED METHOD TO DETECT MILD ALZHEIMER’S DISEASE USING EVENT-RELATED POTENTIALSJ Prev Alz Dis 2016;3(2):101-10418
PSYCHOMETRIC EVALUATION OF THE NEUROPSYCHOLOGICAL TEST BATTERY IN INDIVIDUALS WITH NORMAL COGNITION, MILD COGNITIVE IMPAIRMENT, OR MILD TO MODERATE ALZHEIMER’S DISEASE: RESULTS FROM A LONGITUDINAL STUDYJ Prev Alz Dis 2018;5(4):236-24418
DESIGNING TRIALS OF DISEASE MODIFYING AGENTS FOR EARLY AND PRECLINICAL ALZHEIMER’S DISEASE INTERVENTION: WHAT EVIDENCE IS MEANINGFUL TO PATIENTS, PROVIDERS, AND PAYERS?J Prev Alz Dis 2019;6(1):20-2618
AADVAC1, AN ACTIVE IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE AND NON ALZHEIMER TAUOPATHIES: AN OVERVIEW OF PRECLINICAL AND CLINICAL DEVELOPMENTJ Prev Alz Dis 2019;6(1):63-6918
COMMENT: HIGH ALZHEIMER’S DISEASE STUDY COMPLEXITY - LOW SUCCESS RATEJ Prev Alz Dis 2014;1(1):11-1217
CEREAL INTAKE INCREASES AND DAIRY PRODUCTS DECREASE RISK OF COGNITIVE DECLINE AMONG ELDERLY FEMALE JAPANESEJ Prev Alz Dis 2014;1(3):160-16717
THREE CARDINAL LESSONS FROM ADAPT – 10 YEARS ONJ Prev Alz Dis 2014;1(3):176-18017
NEUROPSYCHOLOGICAL PROFILE OF “COGNITIVE FRAILTY” SUBJECTS IN MAPT STUDYJ Prev Alz Dis 2016;3(3):151-15917
THE PARADOX OF RESEARCH ON DEMENTIA-ALZHEIMER’S DISEASEJ Prev Alz Dis 2016;3(4):189-19117
SWINGS AND ROUNDABOUTS IN CNS DRUG BIOMARKERSJ Prev Alz Dis 2017;4(3):134-13517
BRAIN DONATION BY PROXY: ARE THERE PREDICTORS IN NEURODEGENERATIVE DEMENTIA?J Prev Alz Dis 2014;1(3):151-15916
INTEGRATING INFORMATION FROM FDG - AND AMYLOID PET FOR DETECTING DIFFERENT TYPES OF DEMENTIA IN OLDER PERSONS. A CASE-SERIES STUDYJ Prev Alz Dis 2016;3(3):127-13216
FEMALE SEX AND ALZHEIMER’S RISK: THE MENOPAUSE CONNECTIONJ Prev Alz Dis 2018;5(4):225-23016
REPORT FROM THE FIRST CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) ASIA-CHINA 2018 : BRINGING TOGETHER GLOBAL LEADERSJ Prev Alz Dis 2019;6(2):144-14716
DIETARY FAT INTAKE AND COGNITIVE FUNCTION AMONG OLDER POPULATIONS: A SYSTEMATIC REVIEW AND META-ANALYSISJ Prev Alz Dis 2019;6(3):204-21116
COMPARING THE STANDARD AND ELECTRONIC VERSIONS OF THE ALZHEIMER’S DISEASE ASSESSMENT SCALE – COGNITIVE SUBSCALE: A VALIDATION STUDYJ Prev Alz Dis 2019;6(4):237-24116
COMMENT : CLINICAL TRIALS FOR ALZHEIMER’S DISEASE TURNED A CORNER IN 2013’ J Prev Alz Dis 2014;1(2):71-7315
CLINICAL EFFECTS OF ORAL TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATIONJ Prev Alz Dis 2017;4(3):136-13715
AURAPTENE IN THE PEELS OF CITRUS KAWACHIENSIS (KAWACHIBANKAN) CONTRIBUTES TO THE PRESERVATION OF COGNITIVE FUNCTION: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN HEALTHY VOLUNTEERSJ Prev Alz Dis 2018;5(3):197-20115
DIABETES MELLITUS AND COGNITIVE DECLINE – PREVENTION SHOULD NOT BE DELAYED!J Prev Alz Dis 2018;5(2):95-9715
FEASIBILITY OF USING A WEARABLE BIOSENSOR DEVICE IN PATIENTS AT RISK FOR ALZHEIMER’S DISEASE DEMENTIAJ Prev Alz Dis 2020;7(2):104-11115
MEDITERRANEAN DIET AND MAGNETIC RESONANCE IMAGING-ASSESSED BRAIN ATROPHY IN COGNITIVELY NORMAL INDIVIDUALS AT RISK FOR ALZHEIMER’S DISEASEJ Prev Alz Dis 2014;1(1):23-3214
HIPPOCAMPAL ASTROCYTES AND ALZHEIMER’S DISEASE J Prev Alz Dis 2014;1(2):124-12814
JPAD IS MOVING FASTJ Prev Alz Dis 2016;3(1):3-414
ANTIOXIDANTS IN THE DIET AND COGNITIVE FUNCTION: WHICH ROLE FOR THE MEDITERRANEAN LIFE-STYLE?J Prev Alz Dis 2017;4(1):58-6414
EPIGALLOCATECHIN 3-GALLATE AS AN INHIBITOR OF TAU PHOSPHORYLATION AND AGGREGATION: A MOLECULAR AND STRUCTURAL INSIGHTJ Prev Alz Dis 2017;4(4):218-22514
WHO GUIDELINES ON COMMUNITY-LEVEL INTERVENTIONS TO MANAGE DECLINES IN INTRINSIC CAPACITY: THE ROAD TO PREVENTION COGNITIVE DECLINE IN OLDER AGE?J Prev Alz Dis 2018;5(3):165-16714
INCREASED FUNCTIONAL CONNECTIVITY AFTER LISTENING TO FAVORED MUSIC IN ADULTS WITH ALZHEIMER DEMENTIAJ Prev Alz Dis 2019;6(1):56-6214
IMPLEMENTING A MEMORY CLINIC MODEL TO FACILITATE RECRUITMENT INTO EARLY PHASE CLINICAL TRIALS FOR MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASEJ Prev Alz Dis 2019;6(2):135-13814
OVERTREATING ALZHEIMER’S DISEASEJ Prev Alz Dis 2021;2(8):234-23614
PREDICTION OF COGNITIVE DECLINE FOR ENRICHMENT OF ALZHEIMER’S DISEASE CLINICAL TRIALSJ Prev Alz Dis 2022;3(9):400-40914
HIGHER COGNITIVE PERFORMANCE IS PROSPECTIVELY ASSOCIATED WITH HEALTHY DIETARY CHOICES: THE MAINE SYRACUSE LONGITUDINAL STUDYJ Prev Alz Dis 2015;2(1):24-3213
DIABETES MITIGATES THE ROLE OF MEMORY COMPLAINT IN PREDICTING DEMENTIA RISK: RESULTS FROM THE PREVENTION OF ALZHEIMER’S DISEASE WITH VITAMIN E AND SELENIUM STUDYJ Prev Alz Dis 2017;4(3):143-14813
CARE MANAGEMENT TO PROMOTE TREATMENT ADHERENCE IN PATIENTS WITH COGNITIVE IMPAIRMENT AND VASCULAR RISK FACTORS: A DEMONSTRATION PROJECTJ Prev Alz Dis 2018;5(1):36-4113
COGNITIVE FRAILTY AND INCIDENCE OF DEMENTIA IN OLDER PERSONSJ Prev Alz Dis 2018;5(1):42-4813
ANALYSIS OF THE RELATIONSHIP OF COGNITIVE IMPAIRMENT AND FUNCTIONAL IMPAIRMENT IN MILD ALZHEIMER’S DISEASE IN EXPEDITION 3J Prev Alz Dis 2018;5(3):184-18713
EFFECTIVENESS OF THE OPEN SCREENING PROGRAMS IN RECRUITING SUBJECTS TO PRODROMAL AND MILD ALZHEIMER’S DISEASE CLINICAL TRIALSJ Prev Alz Dis 2020;4(7):251-25513
COST-EFFECTIVENESS OF DEMENTIA PREVENTION INTERVENTIONSJ Prev Alz Dis 2021;2(8):210-21713
MEMORY BROUGHT TO MIND. FIVE-YEAR FOLLOW-UP OF CASE FINDING AND INTERVENTION OF DEMENTIA IN A SWEDISH PRIMARY HEALTH CARE DISTRICTJ Prev Alz Dis 2015;2(1):17-2312
IMAGING VASCULAR DISEASE AND AMYLOID IN THE AGING BRAIN: IMPLICATIONS FOR TREATMENTJ Prev Alz Dis 2015;2(1):64-7012
THE EFFECT OF VASCULAR NEUROPATHOLOGY ON LATE-LIFE COGNITION: RESULTS FROM THE SMART PROJECTJ Prev Alz Dis 2016;3(2):85-9112
SHORT-TERM PRACTICE EFFECTS AND AMYLOID DEPOSITION: PROVIDING INFORMATION ABOVE AND BEYOND BASELINE COGNITIONJ Prev Alz Dis 2017;4(2):87-9212
COMBINING GEOSPATIAL ANALYSIS WITH DEMENTIA RISK UTILISING GENERAL PRACTICE DATA: A SYSTEMATIC REVIEWJ Prev Alz Dis 2018;5(1):71-7712
PROSPECTS FOR EFFECTIVE TREATMENT OF THE DEMENTIA-ALZHEIMER SYNDROME: A RENEWED ODYSSEY IN SEARCH OF THE MAGIC ELIXIRJ Prev Alz Dis 2017;4(4):215-21712
ASSESSMENT OF INSTRUMENTAL ACTIVITIES OF DAILY LIVING IN OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE USING THE VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT TOOL (VRFCAT)J Prev Alz Dis 2018;5(4):216-22412
BIOLOGICAL AND COGNITIVE MARKERS OF PRESENILIN1 E280A AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE: A COMPREHENSIVE REVIEW OF THE COLOMBIAN KINDREDJ Prev Alz Dis 2019;6(2):112-12012
GEROSCIENCE AND THE ROLE OF AGING IN THE ETIOLOGY AND MANAGEMENT OF ALZHEIMER’S DISEASEJ Prev Alz Dis 2020;7(1):2-312
DATA-DRIVEN PARTICIPANT RECRUITMENT: FINDINGS FROM THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE 3J Prev Alz Dis 2020;7(2):122-12712
A MACHINE LEARNING FRAMEWORK FOR ASSESSMENT OF COGNITIVE AND FUNCTIONAL IMPAIRMENTS IN ALZHEIMER’S DISEASE: DATA PREPROCESSING AND ANALYSISJ Prev Alz Dis 2020;7(2):87-9412
CURRENT STATE OF SELF-ADMINISTERED BRIEF COMPUTERIZED COGNITIVE ASSESSMENTS FOR DETECTION OF COGNITIVE DISORDERS IN OLDER ADULTS: A SYSTEMATIC REVIEWJ Prev Alz Dis 2021;3(8):267-27612
THE UPS AND DOWNS OF AMYLOID IN ALZHEIMER’SJ Prev Alz Dis 2022;1(9):92-9512
THE TIMECOURSE OF GLOBAL COGNITIVE GAINS FROM SUPERVISED COMPUTER-ASSISTED COGNITIVE TRAINING: A RANDOMISED, ACTIVE-CONTROLLED TRIAL IN ELDERLY WITH MULTIPLE DEMENTIA RISK FACTORSJ Prev Alz Dis 2014;1(1):33-3911
THE RELATIONSHIP OF HEMOGLOBIN LEVELS, DELIRIUM AND COGNITIVE STATUS IN HOSPITALIZED GERIATRIC PATIENTS: RESULTS FROM THE CRIME STUDYJ Prev Alz Dis 2015;2(3):178-18311
NEW FINDINGS WITH REANALYSIS OF THE DOMINO TRIAL ?J Prev Alz Dis 2015;2(3):21211
ASSESSING THE RELATIONSHIP BETWEEN VITAMIN D STATUS AND IMPAIRMENTS IN COGNITIVE AND PHYSICAL PERFORMANCE IN OLDER ADULTS USING A DUAL TASK PHYSICAL PERFORMANCE TEST J Prev Alz Dis 2017;4(1):29-3611
ASSOCIATIONS OF LONG-TERM TEA CONSUMPTION WITH DEPRESSIVE AND ANXIETY SYMPTOMS IN COMMUNITY-LIVING ELDERLY: FINDINGS FROM THE DIET AND HEALTHY AGING STUDYJ Prev Alz Dis 2018;5(1):21-2511
EFFECTS OF A SIX-MONTH MULTI-INGREDIENT NUTRITION SUPPLEMENT INTERVENTION OF OMEGA-3 POLYUNSATURATED FATTY ACIDS, VITAMIN D, RESVERATROL, AND WHEY PROTEIN ON COGNITIVE FUNCTION IN OLDER ADULTS: A RANDOMISED, DOUBLE-BLIND, CONTROLLED TRIALJ Prev Alz Dis 2018;5(3):175-18311
MEDITERRANEAN-DASH INTERVENTION FOR NEURODEGENERATIVE DELAY (MIND) DIET SLOWS COGNITIVE DECLINE AFTER STROKEJ Prev Alz Dis 2019;6(4):267-27311
FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESSJ Prev Alz Dis 2020;3(7):195-19611
STIMULUS-LOCKED LATERALIZED READINESS POTENTIAL AND PERFORMANCE: USEFUL MARKERS FOR DIFFERENTIATING BETWEEN AMNESTIC SUBTYPES OF MILD COGNITIVE IMPAIRMENTJ Prev Alz Dis 2017;4(1):21-2810
COGNITIVE PERFORMANCE DOES NOT LIMIT PHYSICAL ACTIVITY PARTICIPATION IN THE LIFESTYLE INTERVENTIONS AND INDEPENDENCE FOR ELDERS PILOT STUDY (LIFE-P)J Prev Alz Dis 2017;4(1):44-5010
SEX AND AGE DIFFERENCES IN THE ASSOCIATION OF BLOOD PRESSURE AND HYPERTENSION WITH COGNITIVE FUNCTION IN THE ELDERLY: THE RANCHO BERNARDO STUDYJ Prev Alz Dis 2017;4(3):165-17310
DEMENTIA: CREATING A KNOWLEDGE-BASED HEALTHCARE PROFESSIONJ Prev Alz Dis 2018;5(1):85-8610
LONG-TERM TEA CONSUMPTION AND DEPRESSIVE AND ANXIETY SYMPTOMS IN ELDERLYJ Prev Alz Dis 2018;5(1):8710
DETECTION OF RATER ERRORS ON COGNITIVE INSTRUMENTS IN A CLINICAL TRIAL SETTINGJ Prev Alz Dis 2018;5(3):188-19610
BIFIDOBACTERIUM BREVE A1 SUPPLEMENTATION IMPROVED COGNITIVE DECLINE IN OLDER ADULTS WITH MILD COGNITIVE IMPAIRMENT: AN OPEN-LABEL, SINGLE-ARM STUDYJ Prev Alz Dis 2019;6(1):70-7510
IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE: CURRENT SCENARIO AND FUTURE PERSPECTIVESJ Prev Alz Dis 2021;4(8):534-55110
INTER-SPECIES GLIA DIFFERENCES: IMPLICATIONS FOR SUCCESSFUL TRANSLATION OF TRANSGENIC RODENT ALZHEIMER’S DISEASE MODEL TREATMENT USING BEXAROTENEJ Prev Alz Dis 2014;1(1):46-509
CURCUMIN MICELLES IMPROVE MITOCHONDRIAL FUNCTION IN A MOUSE MODEL OF ALZHEIMER’S DISEASE J Prev Alz Dis 2014;1(2):80-839
MODERATE, REGULAR ALCOHOL CONSUMPTION IS ASSOCIATED WITH HIGHER COGNITIVE FUNCTION IN OLDER COMMUNITY-DWELLING ADULTSJ Prev Alz Dis 2016;3(2):105-1139
EFFECTS OF THE VACCINE VANUTIDE CRIDIFICAR WITH QS-21 ADJUVANT ON IMMUNOGENICITYJ Prev Alz Dis 2016;3(4):1889
MODEST OVERWEIGHT AND HEALTHY DIETARY HABITS REDUCE RISK OF DEMENTIA: A NATIONWIDE SURVEY IN TAIWANJ Prev Alz Dis 2017;4(1):37-439
OBJECTIVE COGNITIVE IMPAIRMENT AND PROGRESSION TO DEMENTIA IN WOMEN: THE PROSPECTIVE EPIDEMIOLOGICAL RISK FACTOR STUDYJ Prev Alz Dis 2017;4(3):194-2009
EXPANDING THE TOOLKIT FOR STUDIES OF AGINGJ Prev Alz Dis 2017;4(2):69-709
FINANCIAL MANAGEMENT SKILLS IN AGING, MCI AND DEMENTIA: CROSS SECTIONAL RELATIONSHIP TO 18F-FLORBETAPIR PET CORTICAL Β-AMYLOID DEPOSITIONJ Prev Alz Dis 2019;6(4):274-2829
LINKING GEROSCIENCE AND INTEGRATED CARE TO REINFORCE PREVENTIONJ Prev Alz Dis 2020;7(2):68-699
ELEVATED BLOOD HOMOCYSTEINE AND RISK OF ALZHEIMER’S DEMENTIA: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS BASED ON PROSPECTIVE STUDIESJ Prev Alz Dis 2021;3(8):329-3349
COMMENTARY: FUTURE OF ALZHEIMER’S DISEASE TREATMENT: COMBINATION THERAPY AND PRECISION MEDICINEJ Prev Alz Dis 2023;4(10):743-7459
REPLY TO THE LETTER TO THE EDITOR: RESPONSE TO CONCERNS RAISED ON MRI SURVEILLANCE AND CLINICAL IMPLICATIONS OF ARIA IN DISEASE MODIFYING TREATMENTJ Prev Alz Dis 2024;1(11):261-2629
EFFECT OF PUNICALAGIN AND RESVERATROL ON METHIONINE SULFOXIDE REDUCTASE: A POSSIBLE PROTECTIVE CONTRIBUTION AGAINST ALZHEIMER DISEASEJ Prev Alz Dis 2015;2(1):33-378
GINKGETIN AMELIORATES NEUROPATHOLOGICAL CHANGES IN APP/PS1 TRANSGENICAL MICE MODELJ Prev Alz Dis 2016;3(1):24-298
ACTIVITIES OF DAILY LIVING MEASURED BY THE HARVARD AUTOMATED PHONE TASK TRACK WITH COGNITIVE DECLINE OVER TIME IN NON-DEMENTED ELDERLYJ Prev Alz Dis 2017;4(2):81-868
POTENTIAL UTILITY OF PRACTICE EFFECTS IN PREVENTIVE TRIALSJ Prev Alz Dis 2017;4(3):140-1428
STRONG RELATIONSHIP BETWEEN MALNUTRITION AND COGNITIVE FRAILTY IN THE SINGAPORE LONGITUDINAL AGEING STUDIES (SLAS-1 AND SLAS-2)J Prev Alz Dis 2018;5(2):142-1488
RESPONSES: LONG-TERM TEA CONSUMPTION AND DEPRESSIVE AND ANXIETY SYMPTOMS IN ELDERLYJ Prev Alz Dis 2018;5(1):878
CROSS-SECTIONAL CHARACTERIZATION OF ALBUMIN GLYCATION STATE IN CEREBROSPINAL FLUID AND PLASMA FROM ALZHEIMER’S DISEASE PATIENTSJ Prev Alz Dis 2019;6(2):139-1438
SHIFT IN HOSPITALIZATIONS FOR ALZHEIMER’S DISEASE TO RELATED DEMENTIAS IN FRANCE BETWEEN 2007 AND 2017J Prev Alz Dis 2019;6(2):108-1118
NEUROPSYCHOLOGICAL, PSYCHIATRIC, AND FUNCTIONAL CORRELATES OF CLINICAL TRIAL ENROLLMENTJ Prev Alz Dis 2019;6(4):242-2478
SENSITIVITY OF THE PRECLINICAL ALZHEIMER’S COGNITIVE COMPOSITE (PACC), PACC5, AND REPEATABLE BATTERY FOR NEUROPSYCHOLOGICAL STATUS (RBANS) TO AMYLOID STATUS IN PRECLINICAL ALZHEIMER’S DISEASE -ATABECESTAT PHASE 2B/3 EARLY CLINICAL TRIALJ Prev Alz Dis 2022;2(9):255-2618
EFFECTIVENESS OF PHYSICAL EXERCISE ON ALZHEIMER’S DISEASE. A SYSTEMATIC REVIEWJ Prev Alz Dis 2022;4(9):601-6168
FORECASTING THE PREVALENCE OF ALZHEIMER’S DISEASE AT MILD COGNITIVE IMPAIRMENT AND MILD DEMENTIA STAGES IN FRANCE IN 2022J Prev Alz Dis 2023;2(10):259-2668
THE ROOM WHERE IT HAPPENS: CLINICIAN REFLECTIONS ON RETURNING PRECLINICAL ALZHEIMER’S BIOMARKER RESULTS TO RESEARCH PARTICIPANTSJ Prev Alz Dis 2024;1(11):1-68
NEUROPROTECTIVE EFFECTS OF A VARIETY OF POMEGRANATE JUICE EXTRACTS (PJE) AGAINST THE EXCITOTOXIN QUINOLINIC ACID IN HUMAN PRIMARY NEURONS J Prev Alz Dis 2014;1(2):84-907
LETTER TO THE EDITOR: PREVENTING DEMENTIA THROUGH COMMUNITY INVOLVEMENT AND ALTRUISTIC BEHAVIORSJ Prev Alz Dis 2018;5(4):259-2607
GEOGRAPHIC CLUSTERS OF ALZHEIMER’S DISEASE MORTALITY RATES IN THE USA: 2008-2012J Prev Alz Dis 2018;5(4):231-2357
MRI CLINICAL RATINGS AND COGNITIVE FUNCTION IN A CROSS-SECTIONAL POPULATION STUDY OF DEMENTIA: THE CACHE COUNTY MEMORY STUDYJ Prev Alz Dis 2019;6(2):100-1077
SELF-ADMINISTERED COGNITIVE TESTING BY OLDER ADULTS AT-RISK FOR COGNITIVE DECLINEJ Prev Alz Dis 2020;4(7):283-2877
THE EU/US TASK FORCE’S FUTURE FOR ANTI-AMYLOID TRIALS: FAITES VOS JEUXJ Prev Alz Dis 2020;3(7):199-2007
NUTRITION TO PREVENT OR TREAT COGNITIVE IMPAIRMENT IN OLDER ADULTS: A GRADE RECOMMENDATIONJ Prev Alz Dis 2021;1(8):110-1167
PROSPECTIVE ASSOCIATIONS BETWEEN PLASMA AMYLOIDBETA 42/40 AND FRAILTY IN COMMUNITY-DWELLING OLDER ADULTSJ Prev Alz Dis 2021;1(8):41-477
SUGAR IN BEVERAGE AND THE RISK OF INCIDENT DEMENTIA, ALZHEIMER’S DISEASE AND STROKE: A PROSPECTIVE COHORT STUDYJ Prev Alz Dis 2021;2(8):188-1937
A WEB-BASED MULTIDOMAIN LIFESTYLE INTERVENTION FOR OLDER ADULTS: THE EMIND RANDOMIZED CONTROLLED TRIALJ Prev Alz Dis 2021;2(8):142-1507
EFFECTS OF FOLIC ACID AND VITAMIN B12 SUPPLEMENTATION ON COGNITIVE IMPAIRMENT AND INFLAMMATION IN PATIENTS WITH ALZHEIMER’S DISEASE: A RANDOMIZED, SINGLE-BLINDED, PLACEBO-CONTROLLED TRIALJ Prev Alz Dis 2021;3(8):249-2567
PREVENTION OF ALZHEIMER’S DISEASE AND COGNITIVE DECLINE WITH DIET & LIFESTYLE: PROCEEDINGS OF THE A. G. LEVENTIS FOUNDATION CONFERENCEJ Prev Alz Dis 2023;1(10):137-1437
ASSOCIATIONS OF STAGES OF OBJECTIVE MEMORY IMPAIRMENT WITH CEREBROSPINAL FLUID AND NEUROIMAGING BIOMARKERS OF ALZHEIMER’S DISEASEJ Prev Alz Dis 2023;1(10):112-1197
PREDICTIVE UTILITY OF PLASMA AMYLOID AND TAU FOR COGNITIVE DECLINE IN COGNITIVELY NORMAL ADULTSJ Prev Alz Dis 2023;2(10):178-1857
INITIAL EXPERIENCES WITH AMYLOID-RELATED IMAGING ABNORMALITIES IN PATIENTS RECEIVING ADUCANUMAB FOLLOWING ACCELERATED APPROVALJ Prev Alz Dis 2023;4(10):765-7707
CTAD TASK FORCE PAPER - NEUROPSYCHIATRIC SYMPTOMS IN AD: CLINICAL TRIALS TARGETING MILD BEHAVIORAL IMPAIRMENT: A REPORT FROM THE INTERNATIONAL CTAD TASK FORCEJ Prev Alz Dis 2024;1(11):56-647
AGING, SENESCENCE, AND DEMENTIAJ Prev Alz Dis 2022;3(9):523-5316
THE EFFECTS OF SUBJECTIVE COGNITIVE DECLINE ON APOE GENOTYPE DISCLOSURE IN THE BUTLER HOSPITAL ALZHEIMER’S PREVENTION REGISTRYJ Prev Alz Dis 2023;2(10):152-1616
A PRAGMATIC, INVESTIGATOR-DRIVEN PROCESS FOR DISCLOSURE OF AMYLOID PET SCAN RESULTS TO ADNI-4 RESEARCH PARTICIPANTSJ Prev Alz Dis 2024;2(11):294-3026
EFFECTS OF COMPUTERIZED COGNITIVE TRAINING ON GAIT SPEED IN COMMUNITY DWELLING OLDER ADULTS, A PILOT STUDYJ Prev Alz Dis 2016;3(3):145-1505
DEVELOPMENT OF AN UPSA SHORT FORM FOR USE IN LONGITUDINAL STUDIES IN THE EARLY ALZHEIMER’S DISEASE SPECTRUMJ Prev Alz Dis 2020;3(7):179-1835
AN INDUSTRY PERSPECTIVE: FUTURE OF ANTI-AMYLOID TRIALSJ Prev Alz Dis 2020;3(7):142-1435
A IS FOR AMYLOIDJ Prev Alz Dis 2020;3(7):140-1415
A JAPANESE MULTICENTER STUDY ON PET AND OTHER BIOMARKERS FOR SUBJECTS WITH POTENTIAL PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASEJ Prev Alz Dis 2021;4(8):495-5025
COHORT-SPECIFIC OPTIMIZATION OF MODELS PREDICTING PRECLINICAL ALZHEIMER’S DISEASE, TO ENHANCE SCREENING PERFORMANCE IN THE MIDDLE OF PRECLINICAL ALZHEIMER’S DISEASE CLINICAL STUDIESJ Prev Alz Dis 2021;4(8):503-5125
DISEASE BURDEN AND ATTRIBUTABLE RISK FACTORS OF ALZHEIMER’S DISEASE AND DEMENTIA IN CHINA FROM 1990 TO 2019J Prev Alz Dis 2022;2(9):306-3145
CLINICAL RESEARCH INVESTIGATING ALZHEIMER’S DISEASE IN CHINA: CURRENT STATUS AND FUTURE PERSPECTIVES TOWARD PREVENTIONJ Prev Alz Dis 2022;3(9):532-5415
DEMOGRAPHIC ANALYSIS OF INDUSTRY-SPONSORED ALZHEIMER’S DISEASE TRIAL POPULATIONS IN THE UNITED STATESJ Prev Alz Dis 2023;1(10):130-1325
PHARMACOLOGICAL INVENTIONS FOR ALZHEIMER TREATMENT IN THE UNITED STATES OF AMERICA: A REVISION PATENT FROM 2010 – 2020J Prev Alz Dis 2023;1(10):50-685
MEDICAL JOURNEY OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND MILD ALZHEIMER’S DISEASE DEMENTIA: A CROSS-SECTIONAL SURVEY OF PATIENTS, CARE PARTNERS, AND NEUROLOGISTSJ Prev Alz Dis 2023;2(10):162-1705
LONGITUDINAL EXPOSURE–RESPONSE MODELING OF MULTIPLE INDICATORS OF ALZHEIMER’S DISEASE PROGRESSIONJ Prev Alz Dis 2023;2(10):212-2225
NEUROINFLAMMATION BIOMARKERS IN THE AT(N) FRAMEWORK ACROSS THE ALZHEIMER’S DISEASE CONTINUUMJ Prev Alz Dis 2023;3(10):401-4175
LETTER TO THE EDITOR: FIRST EXPERIENCES WITH AMYLOID-RELATED IMAGING ABNORMALITIES – YET WITHOUT IMAGING THAT CAN RULE OUT CEREBRAL INJURY OR MONITOR EFFICACY OF RECOMMENDED MANAGEMENTJ Prev Alz Dis 2024;1(11):259-2605
CLINICAL CORRELATES OF THE PET-BASED BRAAK STAGING FRAMEWORK IN ALZHEIMER’S DISEASEJ Prev Alz Dis 2024;2(11):414-4215
EFFECTS OF A GROUP-BASED 8-WEEK MULTICOMPONENT COGNITIVE TRAINING ON COGNITION, MOOD AND ACTIVITIES OF DAILY LIVING AMONG HEALTHY OLDER ADULTS: A ONE-YEAR FOLLOW-UP OF A RANDOMIZED CONTROLLED TRIALJ Prev Alz Dis 2020;7(2):112-1214
SEARCHING FOR THE HOLY GRAIL WILL NEED BIOMARKERSJ Prev Alz Dis 2020;7(1):4-64
IS RELUCTANCE TO SHARE ALZHEIMER’S DISEASE BIOMARKER STATUS WITH A STUDY PARTNER A BARRIER TO PRECLINICAL TRIAL RECRUITMENT?J Prev Alz Dis 2021;1(8):52-584
A NOVEL COMPUTERIZED COGNITIVE STRESS TEST TO DETECT MILD COGNITIVE IMPAIRMENTJ Prev Alz Dis 2021;2(8):135-1414
ENVIRONMENTAL DISTRACTIONS DURING UNSUPERVISED REMOTE DIGITAL COGNITIVE ASSESSMENTJ Prev Alz Dis 2021;3(8):263-2664
QUANTIFYING RECRUITMENT SOURCE AND PARTICIPANT COMMUNICATION PREFERENCES FOR ALZHEIMER’S DISEASE PREVENTION RESEARCHJ Prev Alz Dis 2021;3(8):299-3054
PERIPHERAL BLOOD BRCA1 METHYLATION POSITIVELY CORRELATES WITH MAJOR ALZHEIMER’S DISEASE RISK FACTORSJ Prev Alz Dis 2021;4(8):477-4824
THE ASSOCIATION BETWEEN PEANUT AND PEANUT BUTTER CONSUMPTION AND COGNITIVE FUNCTION AMONG COMMUNITY-DWELLING OLDER ADULTSJ Prev Alz Dis 2021;4(8):436-4414
RECRUITMENT OF OLDER AFRICAN AMERICANS IN ALZHEIMER’S DISEASE CLINICAL TRIALS USING A COMMUNITY EDUCATION APPROACHJ Prev Alz Dis 2022;4(9):672-6784
US ADULTS’ LIKELIHOOD TO PARTICIPATE IN DEMENTIA PREVENTION DRUG TRIALS: RESULTS FROM THE NATIONAL POLL ON HEALTHY AGINGJ Prev Alz Dis 2023;1(10):34-404
FRUCTOSE CONSUMPTION IS ASSOCIATED WITH A HIGHER RISK OF DEMENTIA AND ALZHEIMER’S DISEASE: A PROSPECTIVE COHORT STUDYJ Prev Alz Dis 2023;2(10):186-1924
ADDING THE TOPOGRAPHICAL INFORMATION FROM TAU-PET TO THE A/T/(N) FRAMEWORK: STEPS TOWARDS STAGING AD IN VIVOJ Prev Alz Dis 2023;3(10):381-3864
REPRODUCTIVE MARKERS IN ALZHEIMER’S DISEASE PROGRESSION: THE FRAMINGHAM HEART STUDYJ Prev Alz Dis 2023;3(10):530-5354
ASSOCIATION BETWEEN LONGITUDINAL CEREBROSPINAL FLUID ALZHEIMER’S BIOMARKERS AND THE LIFESTYLE FOR BRAIN HEALTH (LIBRA) INDEX: FINDINGS FROM THE EUROPEAN PREVENTION OF ALZHEIMER’S DEMENTIA COHORT STUDY (EPAD LCS)J Prev Alz Dis 2023;3(10):543-5504
METFORMIN IN THE PREVENTION OF ALZHEIMER’S DISEASE AND ALZHEIMER’S DISEASE RELATED DEMENTIASJ Prev Alz Dis 2023;4(10):706-7174
POTENTIAL IMPLICATIONS OF SLOWING DISEASE PROGRESSION IN AMYLOID-POSITIVE EARLY ALZHEIMER’S DISEASE: ESTIMATES FROM REAL-WORLD DATAJ Prev Alz Dis 2024;2(11):310-3194
AT-HOME ADMINISTRATION OF GANTENERUMAB BY CARE PARTNERS TO PEOPLE WITH EARLY ALZHEIMER’S DISEASE: FEASIBILITY, SAFETY AND PHARMACODYNAMIC IMPACTJ Prev Alz Dis 2024;3(11):537-5484
NEUROPROTECTIVE EFFECTS OF GUARANA (PAULLINIA CUPANA MART.) AGAINST VINCRISTINE IN VITRO EXPOSUREJ Prev Alz Dis 2018;5(1):65-703
EFFECTS OF RICE WINE LEES ON COGNITIVE FUNCTION IN COMMUNITY-DWELLING PHYSICALLY ACTIVE OLDER ADULTS: A PILOT RANDOMIZED CONTROLLED TRIALJ Prev Alz Dis 2020;7(2):95-1033
THE PATIENT IN YOUR ALZHEIMER’S DISEASE STUDY MAY BE IN ANOTHER: DUPLICATION AND DECEPTION IN CLINICAL TRIALS OF ALZHEIMER’S DISEASEJ Prev Alz Dis 2020;7(1):43-463
EXPLORING FACTORS THAT CONTRIBUTE TO JOINING AND REGULARLY PRACTICING IN COGNITIVE TRAINING AMONG HEALTHY OLDER ADULTS: A ONE-YEAR FOLLOW-UP QUALITATIVE STUDYJ Prev Alz Dis 2020;7(2):75-813
COMMUNICATING PERSONAL RISK PROFILES OF ALZHEIMER’S DISEASE TO OLDER ADULTS: A PILOT TRIALJ Prev Alz Dis 2022;1(9):144-1503
REPRESENTATION OF RACIAL AND ETHNIC MINORITY POPULATIONS IN DEMENTIA PREVENTION TRIALS: A SYSTEMATIC REVIEWJ Prev Alz Dis 2022;1(9):113-1183
KETONE ESTER EFFECTS ON BIOMARKERS OF BRAIN METABOLISM AND COGNITIVE PERFORMANCE IN COGNITIVELY INTACT ADULTS ≥ 55 YEARS OLD. A STUDY PROTOCOL FOR A DOUBLEBLINDED RANDOMIZED CONTROLLED CLINICAL TRIALJ Prev Alz Dis 2022;1(9):54-663
INTERVENTION FOR COGNITIVE RESERVE ENHANCEMENT IN DELAYING THE ONSET OF ALZHEIMER’S SYMPTOMATIC EXPRESSION (INCREASE) STUDY: RESULTS FROM A RANDOMIZED CONTROLLED STUDY OF MEDICATION THERAPY MANAGEMENT TARGETING A DELAY IN PRODROMAL DEMENTIA SYMPTOM PROGRESSIONJ Prev Alz Dis 2022;4(9):646-6543
A HIERARCHICAL BAYESIAN LATENT CLASS MODEL FOR THE DIAGNOSTIC PERFORMANCE OF MINI-MENTAL STATE EXAMINATION AND MONTREAL COGNITIVE ASSESSMENT IN SCREENING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASEJ Prev Alz Dis 2022;4(9):589-6003
LETTER TO THE EDITOR: GENETICALLY DETERMINED ALZHEIMER’S DISEASE IS ASSOCIATED WITH INCREASED RISK OF VARICOSE VEIN: A MENDELIAN RANDOMIZATION STUDYJ Prev Alz Dis 2022;4(9):816-8173
SCREENING OVER SPEECH IN UNSELECTED POPULATIONS FOR CLINICAL TRIALS IN AD (PROSPECT-AD): STUDY DESIGN AND PROTOCOLJ Prev Alz Dis 2023;2(10):314-3213
EXPECTANCY DOES NOT PREDICT 18-MONTH TREATMENT OUTCOMES WITH COGNITIVE TRAINING IN MILD COGNITIVE IMPAIRMENTJ Prev Alz Dis 2024;1(11):71-783
WHITE MATTER HYPERINTENSITY AS A VASCULAR CONTRIBUTION TO THE AT(N) FRAMEWORKJ Prev Alz Dis 2023;3(10):387-4003
HIGH INTAKE OF DIETARY CHOLESTEROL DECREASES THE RISK OF ALL-CAUSE DEMENTIA AND AD DEMENTIA: A RESULTS FROM FRAMINGHAM OFFSPRING COHORTJ Prev Alz Dis 2023;4(10):748-7553
PLASMA OLIGOMER Β-AMYLOID AND WHITE MATTER MICROSTRUCTURAL INTEGRITY IN COGNITIVELY NORMAL OLDER ADULTS ACCORDING TO CEREBRAL AMYLOID DEPOSITIONJ Prev Alz Dis 2023;4(10):837-8463
PHASE 1/2A INTRAVENOUS AND SUBCUTANEOUS OLIGOMERSPECIFIC ANTIBODY KHK6640 IN MILD TO MODERATE ALZHEIMER’S DISEASEJ Prev Alz Dis 2024;1(11):65-703
ETHICAL CONSIDERATIONS AT THE INTERSECTION OF SOCIAL MEDIA AND DEMENTIA PREVENTION RESEARCHJ Prev Alz Dis 2024;2(11):274-2843
EDITORIAL : ALZHEIMER’S DISEASE PREVENTION: REALITY OR UTOPIA?2
EFFECTS ON COGNITION OF BERRY, POMEGRANATE, GRAPE AND BIOPHENOLS: A GENERAL REVIEW2
INTEGRATING BIOMARKER OUTCOMES INTO CLINICAL TRIALS FOR ALZHEIMER’S DISEASE IN DOWN SYNDROMEJ Prev Alz Dis 2021;1(8):48-512
MENTAL COMPONENT SCORE (MCS) FROM HEALTH-RELATED QUALITY OF LIFE PREDICTS INCIDENCE OF DEMENTIA IN U.S. MALESJ Prev Alz Dis 2021;2(8):169-1742
A SYSTEMATIC REVIEW ON THE FEASIBILITY OF SALIVARY BIOMARKERS FOR ALZHEIMER’S DISEASEJ Prev Alz Dis 2021;1(8):84-912
EXECUTIVE FUNCTION PREDICTS THE VALIDITY OF SUBJECTIVE MEMORY COMPLAINTS IN OLDER ADULTS BEYOND DEMOGRAPHIC, EMOTIONAL, AND CLINICAL FACTORSJ Prev Alz Dis 2021;2(8):161-1682
DOES TEA DRINKING PROMOTE HEALTH OF OLDER ADULTS: EVIDENCE FROM THE CHINA HEALTH AND NUTRITION SURVEYJ Prev Alz Dis 2021;2(8):194-1982
DETERMINANTS OF MEDICAL DIRECT COSTS OF CARE AMONG PATIENTS OF A MEMORY CENTERJ Prev Alz Dis 2021;3(8):351-3612
MAIL AND TELEPHONE OUTREACH FROM ELECTRONIC HEALTH RECORDS FOR RESEARCH PARTICIPATION ON COGNITIVE HEALTH AND AGINGJ Prev Alz Dis 2021;3(8):292-2982
SENOLYTIC THERAPY TO MODULATE THE PROGRESSION OF ALZHEIMER’S DISEASE (STOMP-AD): A PILOT CLINICAL TRIALJ Prev Alz Dis 2022;1(9):22-292
IS “PRE-PRECLINICAL AD” HELPFUL TO THE EU/US CTAD TASK FORCE?J Prev Alz Dis 2022;1(9):1842
ANXIETY AND DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID-Β BURDEN IN COGNITIVELY UNIMPAIRED OLDER ADULTSJ Prev Alz Dis 2022;2(9):286-2962
EVERYDAY FUNCTIONING AND ENTORHINAL AND INFERIOR TEMPORAL TAU BURDEN IN COGNITIVELY NORMAL OLDER ADULTSJ Prev Alz Dis 2022;4(9):801-8082
ASSOCIATION OF A MIND DIET WITH BRAIN STRUCTURE AND DEMENTIA IN A FRENCH POPULATIONJ Prev Alz Dis 2022;4(9):655-6642
ALZHEIMER’S DISEASE CLINICAL TRIAL RESEARCH ADAPTATION FOLLOWING COVID-19 PANDEMIC ONSET: NATIONAL SAMPLE OF ALZHEIMER’S CLINICAL TRIAL CONSORTIUM SITESJ Prev Alz Dis 2022;4(9):665-6712
AGE, SEX, HYPERTENSIONANDHDL-CALTERSERUMBACE1ACTIVITY IN COGNITIVELY NORMAL SUBJECTS: IMPLICATIONS FOR ALZHEIMER’S DISEASEJ Prev Alz Dis 2022;4(9):708-7142
PROGRAMMED DEATH OF MICROGLIA IN ALZHEIMER’S DISEASE: AUTOPHAGY, FERROPTOSIS, AND PYROPTOSISJ Prev Alz Dis 2023;1(10):95-1032
RISK ESTIMATES OF DEMENTIA AND ALZHEIMER’S DISEASE AMONG DIFFERENT WHOLE GRAIN FOOD CONSUMPTION CATEGORIES: A PILOT STUDYJ Prev Alz Dis 2023;1(10):133-1362
MEDICAL AND PSYCHIATRIC RISK FACTORS FOR DEMENTIA IN VETERANS WITH AND WITHOUT TRAUMATIC BRAIN INJURY (TBI): A NATIONWIDE COHORT STUDYJ Prev Alz Dis 2023;2(10):244-2502
A GENETIC VALIDATION OF THE NEURODEGENERATION BIOMARKERS TAU-A AND TAU-C - A MENDELIAN RANDOMIZATION STUDYJ Prev Alz Dis 2023;3(10):536-5422
GENOTYPIC EFFECTS OF THE TOMM40’523 VARIANT AND APOE ON LONGITUDINAL COGNITIVE CHANGE OVER 4 YEARS: THE TOMMORROW STUDYJ Prev Alz Dis 2023;4(10):886-8942
ERRATUM TO: CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION POTENTIALJ Prev Alz Dis 2024;1(11):2642
ALZHEIMER’S DISEASE BIOMARKER DECISION-MAKING AMONG PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND THEIR CARE PARTNERSJ Prev Alz Dis 2024;2(11):285-2932
IMPACT OF DIFFERENTIAL RATES OF DISEASE PROGRESSION IN AMYLOID-POSITIVE EARLY ALZHEIMER’S DISEASE: FINDINGS FROM A LONGITUDINAL COHORT ANALYSISJ Prev Alz Dis 2024;2(11):320-3282
DOMINANTLY INHERITED ALZHEIMER NETWORK TRIALS UNIT (DIAN-TU): TRIAL SATISFACTION AND ATTITUDES TOWARDS FUTURE CLINICAL TRIALSJ Prev Alz Dis 2024;3(11):558-5662
ASSOCIATIONS OF LATER-LIFE EDUCATION, THE BDNF VAL66MET POLYMORPHISM AND COGNITIVE CHANGE IN OLDER ADULTSJ Prev Alz Dis 2020;7(1):37-421
ASSOCIATION OF VITAMIN D LEVELS WITH INCIDENT ALLCAUSE DEMENTIA IN LONGITUDINAL OBSERVATIONAL STUDIES: A SYSTEMATIC REVIEW AND META-ANALYSISJ Prev Alz Dis 2020;7(1):14-201
Clinical Trials and Aging: 12th Conference Clinical Trials on Alzheimer’s Disease, October 4-7, 2019, San Diego, USA1
Clinical Trials and Aging: 12th Conference Clinical Trials on Alzheimer’s Disease, October 4-7, 2019, San Diego, USA1
KNOWLEDGE, ATTITUDE AND PREVENTIVE PRACTICE ON DEMENTIA CARE AMONG PRIMARY HEALTH PROFESSIONALS IN MACAOJ Prev Alz Dis 2020;7(2):83-861
THE EFFECT OF BASELINE PERFORMANCE AND AGE ON COGNITIVE TRAINING IMPROVEMENTS IN OLDER ADULTS: A QUALITATIVE REVIEWJ Prev Alz Dis 2021;1(8):100-1091
PHYSICAL FITNESS AND APOLIPOPROTEIN E GENOTYPE INFLUENCE CORTICAL NETWORKING AND INTELLIGENCE IN ADOLESCENTSJ Prev Alz Dis 2021;1(8):92-991
COMPARATIVE EFFECTIVENESS OF BEHAVIORAL INTERVENTIONS TO PREVENT OR DELAY DEMENTIA: ONEYEAR PARTNER OUTCOMESJ Prev Alz Dis 2021;1(8):33-401
MOLECULAR SUBTYPING OF MILD COGNITIVE IMPAIRMENT BASED ON GENETIC POLYMORPHISM AND GENE EXPRESSIONJ Prev Alz Dis 2021;2(8):224-2331
CHINESE VERSION OF THE BAYLOR PROFOUND MENTAL STATUS EXAMINATION: A BRIEF STAGING MEASURE FOR PATIENTS WITH SEVERE ALZHEIMER’S DISEASEJ Prev Alz Dis 2021;2(8):175-1801
CHILDHOOD SECONDHAND SMOKE EXPOSURE AND RISK OF DEMENTIA, ALZHEIMER’S DISEASE AND STROKE IN ADULTHOOD: A PROSPECTIVE COHORT STUDYJ Prev Alz Dis 2021;3(8):345-3501
DETERMINANTS OF POST-OPERATIVE COGNITIVE DECLINE IN ELDERLY PEOPLEJ Prev Alz Dis 2021;3(8):322-3281
DEVELOPMENT, VALIDATION AND FIELD EVALUATION OF THE SINGAPORE LONGITUDINAL AGEING STUDY (SLAS) RISK INDEX FOR PREDICTION OF MILD COGNITIVE IMPAIRMENT AND DEMENTIAJ Prev Alz Dis 2021;3(8):335-3441
ASSOCIATION OF SUBJECTIVE COGNITIVE DECLINE WITH RISK OF COGNITIVE IMPAIRMENT AND DEMENTIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE LONGITUDINAL STUDIESJ Prev Alz Dis 2021;3(8):277-2851
A FAY-HERRIOT MODEL FOR ESTIMATING SUBJECTIVE COGNITIVE DECLINE AMONG MILITARY VETERANSJ Prev Alz Dis 2021;4(8):457-4611
EARLY-ONSET SUBGROUP OF TYPE 2 DIABETES AND RISK OF DEMENTIA, ALZHEIMER’S DISEASE AND STROKE: A COHORT STUDYJ Prev Alz Dis 2021;4(8):442-4471
DIVERSIFYING RECRUITMENT REGISTRIES: CONSIDERING NEIGHBORHOOD HEALTH METRICSJ Prev Alz Dis 2022;1(9):119-1251
EVALUATION OF MEMANTINE IN AAV-AD RAT: A MODEL OF LATEONSET ALZHEIMER’S DISEASE PREDEMENTIAJ Prev Alz Dis 2022;2(9):338-3471
THE SINGAPORE GERIATRIC INTERVENTION STUDY TO REDUCE COGNITIVE DECLINE AND PHYSICAL FRAILTY (SINGER): STUDY DESIGN AND PROTOCOLJ Prev Alz Dis 2022;1(9):40-481
AT A GLANCE: AN UPDATE ON NEUROIMAGING AND RETINAL IMAGING IN ALZHEIMER’S DISEASE AND RELATED RESEARCHJ Prev Alz Dis 2022;1(9):67-761
STUDY PROTOCOL OF A COMPREHENSIVE ACTIVITY PROMOTIONJ Prev Alz Dis 2022;2(9):376-3841
CEREBRAL PHOSPHO-TAU ACTS SYNERGISTICALLY WITH SOLUBLE AΒ42 LEADING TO MILD COGNITIVE IMPAIRMENT IN AAV-AD RATSJ Prev Alz Dis 2022;3(9):480-4901
INCREASED INCIDENT ALZHEIMER’S DISEASE AMONG INDIVIDUALS WITH VARICOSE VEINS: A POPULATION-BASED COHORT STUDYJ Prev Alz Dis 2022;3(9):441-4481
SUBJECTIVE COGNITIVE DECLINE IN A REGISTRY SAMPLE: RELATION TO PSYCHIATRIC HISTORY, LONELINESS, AND PERSONALITYJ Prev Alz Dis 2022;3(9):435-4401
EFFECTS OF NON-INVASIVE BRAIN STIMULATION ON ALZHEIMER’S DISEASEJ Prev Alz Dis 2022;3(9):410-4241
LETTER TO THE EDITOR: EARLY-ONSET TYPE 2 DIABETES AND RISK OF DEMENTIAJ Prev Alz Dis 2022;3(9):5611
ALZHEIMER\'S DISEASE PREVENTION HEALTH COACHINGJ Prev Alz Dis 2022;2(9):277-2851
SALIVARY ALPHA-AMYLASE ACTIVITY AND MILD COGNITIVE IMPAIRMENT AMONG JAPANESE OLDER ADULTS: THE TOON HEALTH STUDYJ Prev Alz Dis 2022;4(9):752-7571
VALIDATION OF THE SAINT LOUIS UNIVERSITY QUALITY OF LIFE QUESTIONNAIRE IN OLDER ADULTS WITH ALZHEIMER’S DISEASEJ Prev Alz Dis 2022;4(9):809-8121
OBESITY AND BRAIN HEALTH: THE IMPACT OF METABOLIC SYNDROME AND CARDIORESPIRATORY FITNESS ON COGNITIVE PERFORMANCES IN MIDDLE-AGED OBESE WOMENJ Prev Alz Dis 2022;4(9):701-7071
ASSOCIATION OF PREECLAMPSIA WITH INCIDENT DEMENTIA AND ALZHEIMER’S DISEASE AMONG WOMEN IN THE FRAMINGHAM OFFSPRING STUDYJ Prev Alz Dis 2022;4(9):725-7301
OBJECTIVE AND SUBJECTIVE MEASUREMENTS OF MOTOR FUNCTION: RESULTS FROM THE HELIAD STUDYJ Prev Alz Dis 2022;4(9):743-7511
SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ICAPAMESPIB, A SELECTIVE EPICHAPEROME INHIBITOR, IN HEALTHY ADULTSJ Prev Alz Dis 2022;4(9):635-6451
DELAYED DECLINE OF COGNITIVE FUNCTION BY ANTIHYPERTENSIVE AGENTS: A COHORT STUDY LINKED WITH GENOTYPE DATAJ Prev Alz Dis 2022;4(9):679-6911
SOCIOECONOMIC STATUS AND RISKS OF COGNITIVE IMPAIRMENT AND DEMENTIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 39 PROSPECTIVE STUDIESJ Prev Alz Dis 2023;1(10):83-941
AGE- AND SEX-DIFFERENT ASSOCIATIONS BETWEEN COGNITIVE PERFORMANCE AND INFLAMMATORY BIOMARKERS IN COMMUNITY DWELLING OLDER ADULTS: TOWARDS PRECISION PREVENTIVE STRATEGIESJ Prev Alz Dis 2023;1(10):104-1111
EMBRYO SELECTION FOR A CARRIER OF AN EARLY-ONSET ALZHEIMER’S DISEASE-ASSOCIATED MUTATION IN THE PSEN1 GENEJ Prev Alz Dis 2023;1(10):144-1471
ERRATUM TO: CEREBRAL PHOSPHO-TAU ACTS SYNERGISTICALLY WITH SOLUBLE AΒ42 LEADING TO MILD COGNITIVE IMPAIRMENT IN AAV-AD RATSJ Prev Alz Dis 2023;1(10):1501
ERRATUM TO: ALZHEIMER’S DISEASE COMPOSITE SCORE: A POST-HOC ANALYSIS USING DATA FROM THE LIPIDIDIET TRIAL IN PRODROMAL ALZHEIMER’S DISEASEJ Prev Alz Dis 2023;1(10):1511
SUBJECTIVE COGNITIVE COMPLAINTS: COMPARING THE RELATION BETWEEN SELF-REPORTED VERSUS INFORMANTREPORTED SUBJECTIVE COGNITIVE COMPLAINTS AND COGNITIVE PERFORMANCES IN COGNITIVELY UNIMPAIRED, MILD COGNITIVE IMPAIRMENT AND POPULATIONS WITH DEMENTIAJ Prev Alz Dis 2023;3(10):562-5701
LIFESTYLE AND SOCIOECONOMIC TRANSITION AND HEALTH CONSEQUENCES OF ALZHEIMER’S DISEASE AND OTHER DEMENTIAS IN GLOBAL, FROM 1990 TO 2019J Prev Alz Dis 2024;1(11):88-961
ASSOCIATION OF LONELINESS WITH COGNITIVE FUNCTIONSJ Prev Alz Dis 2023;4(10):903-9081
ADULT RENAL DYSFUNCTION AND RISK OF DEMENTIA OR COGNITIVE DECLINE: BRAIN-KIDNEY AXIS HYPOTHESIS BASED ON A SYSTEMATIC REVIEW AND META-ANALYSISJ Prev Alz Dis 2023;3(10):443-4521
USEFULNESS OF COMMUNITY PHARMACY FOR EARLY DETECTION OF COGNITIVE IMPAIRMENT IN OLDER PEOPLE USING THE IQCODE QUESTIONNAIREJ Prev Alz Dis 2023;3(10):488-4961
TEN YEARS AFTER THE NATIONAL ALZHEIMER’S PLAN: DEMENTIA REMAINS A HIDDEN SYNDROME IN FRANCEJ Prev Alz Dis 2023;3(10):600-6061
HIGH-FAT DIET-INDUCED DIABETIC CONDITIONS EXACERBATE COGNITIVE IMPAIRMENT IN A MOUSE MODEL OF ALZHEIMER’S DISEASE VIA A SPECIFIC TAU PHOSPHORYLATION PATTERNJ Prev Alz Dis 2024;1(11):138-1481
A RANDOMIZED PROSPECTIVE SURVEY TARGETING KNOWLEDGE, BARRIERS, FACILITATORS AND READINESS TO PARTICIPATION IN DEMENTIA RESEARCHJ Prev Alz Dis 2023;4(10):790-7991
SOCIAL DETERMINANTS OF HEALTH AMONG OLDER ADULTS WITH DEMENTIA IN URBAN AND RURAL AREASJ Prev Alz Dis 2023;4(10):895-9021
INVESTIGATING THE FACTOR STRUCTURE OF THE PRECLINICAL ALZHEIMER COGNITIVE COMPOSITE AND COGNITIVE FUNCTION INDEX ACROSS RACIAL/ETHNIC, SEX, AND AΒ STATUS GROUPS IN THE A4 STUDYJ Prev Alz Dis 2024;1(11):48-551
RELATIONSHIPS OF HYPNOTICS WITH INCIDENT DEMENTIA AND ALZHEIMER’S DISEASE: A LONGITUDINAL STUDY AND META-ANALYSISJ Prev Alz Dis 2024;1(11):117-1291
THE THERAPEUTIC EFFECTS OF NONINVASIVE BRAIN STIMULATION COMBINED WITH COGNITIVE TRAINING IN ELDERS WITH ALZHEIMER’S DISEASE OR AMNESIC MILD COGNITIVE IMPAIRMENTJ Prev Alz Dis 2024;1(11):222-2291
LETTER TO THE EDITOR: ALZHEIMER’S DISEASE-ASSOCIATED APOE Ε4 FREQUENCIES IN INDIAN POPULATION GENOMES MAY SUGGEST IMPLICATIONS IN LECANEMAB TREATMENTJ Prev Alz Dis 2024;2(11):525-5261
INTEGRATED BIOINFORMATIC ANALYSIS AND VALIDATION IDENTIFIES IMMUNE MICROENVIRONMENT-RELATED POTENTIAL BIOMARKERS IN ALZHEIMER’S DISEASEJ Prev Alz Dis 2024;2(11):495-5061
PERSONALIZED COMPUTATIONAL CAUSAL MODELING OF THE ALZHEIMER DISEASE BIOMARKER CASCADEJ Prev Alz Dis 2024;2(11):435-4441
CARDIOVASCULAR RISK SCALES ASSOCIATION WITH CEREBROSPINAL FLUID ALZHEIMER’S DISEASE BIOMARKERS IN CARDIOVASCULAR LOW CARDIOVASCULAR RISK REGIONSJ Prev Alz Dis 2024;2(11):453-4621
POLYGENIC RISK SCORE REVEALS GENETIC HETEROGENEITY OF ALZHEIMER’S DISEASE BETWEEN THE CHINESE AND EUROPEAN POPULATIONSJ Prev Alz Dis 2024;3(11):701-7091